96 plate ID,96 plate number,96 well,384 plate ID,Plate Map,Well,Human Readable Name,MoleculeID,Concentration,Unit,Vial Code,CAS No.,MW,Target,Salt Data,SMILES,Well X,Well Y,Info
HYCPK547,Plate 1,A01,Inflammation Plate MCE,SP20299LPS,A01,DMSO_A01,DMSO_A01,-1,m,,,,,,,1,1
HYCPK548,Plate 2,A01,Inflammation Plate MCE,SP20299LPS,A02,DMSO_A02,DMSO_A02,-1,m,,,,,,,2,1
HYCPK547,Plate 1,A02,Inflammation Plate MCE,SP20299LPS,A03,SCH 527123,SCH 527123,10,m,b137716,473727-83-2,397.42,CXCR;CXCR,Free Base,O=C1C(C(NC2=CC=CC(C(N(C)C)=O)=C2O)=C1N[C@H](CC)C3=CC=C(O3)C)=O,3,1,"SCH 527123 is a potent; allosteric antagonist of both <b>CXCR1</b> and <b>CXCR2</b>; with <b>IC<sub>50</sub></b> values of 1000 nM and 3-6 nM; respectivelly.
HYCPK548,Plate 2,A02,Inflammation Plate MCE,SP20299LPS,A04,Homoharringtonine,Homoharringtonine,10,m,b133222,26833-87-4,545.62,STAT;STAT,Free Base,[H][C@@]12[C@](CCC3)(C=C(OC)[C@]2(OC([C@](CCCC(O)(C)C)(O)CC(OC)=O)=O)[H])N3CCC4=CC5=C(OCO5)C=C14,4,1,"Homoharringtonine is a cytotoxic alkaloid; induces apoptosis and inhibits <b>STAT3</b> via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
HYCPK547,Plate 1,A03,Inflammation Plate MCE,SP20299LPS,A05,K145 (hydrochloride),K145 (hydrochloride),10,m,b134853,1449240-68-9,384.92,SPHK,Hydrochloride,O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2.[H]Cl,5,1,"K145 is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 _M ; while no inhibition of SphK1 at concentrations up to 10 _M.
HYCPK548,Plate 2,A03,Inflammation Plate MCE,SP20299LPS,A06,Pemirolast (potassium),Pemirolast (potassium),10,m,b145332,100299-08-9,266.3,Histamine Receptor;Histamine Receptor,Potassium,O=C1C(C2=N[N-]N=N2)=CN=C3N1C=CC=C3C.[K+],6,1,"Pemirolast Potassium (BMY 26517) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent.
HYCPK547,Plate 1,A04,Inflammation Plate MCE,SP20299LPS,A07,Amlexanox,Amlexanox,10,m,b141711,68302-57-8,298.29,IKK,Free Acid,O=C(C1=C(N)N=C2C(C(C3=CC(C(C)C)=CC=C3O2)=O)=C1)O,7,1,"AmLexanox is a specific inhibitor of <b>IKK_</b> and <b>TBK1</b>; and inhibits the IKK_ and TBK1 activity determined by MBP phosphorylation with an <b>IC<sub>50</sub></b> of approximately 1-2 _M.
HYCPK548,Plate 2,A04,Inflammation Plate MCE,SP20299LPS,A08,Solcitinib,Solcitinib,10,m,b138845,1206163-45-2,389.45,JAK;JAK;JAK,Free Base,O=C(C1CC1)NC2=NN3C(C4=CC=C(C(N5CC(C)(C)C5)=O)C=C4)=CC=CC3=N2,8,1,"Solcitinib is an orally active; competitive; potent; selective <b>JAK1</b> inhibitor; with an <b>IC<sub>50</sub></b> of 9.8 nM; and 11-; 55- and 23-fold selectivity over JAK2; JAK3 and TYK2; respectively; used in the research of moderate-to-severe plaque-type psoriasis.
HYCPK547,Plate 1,A05,Inflammation Plate MCE,SP20299LPS,A09,Nodinitib-1,Nodinitib-1,10,m,b141503,799264-47-4,287.34,NOD-like Receptor (NLR),Free Base,NC1=NC2=CC=CC=C2N1S(=O)(C3=CC=C(C)C=C3)=O,9,1,"Nodinitib-1 (ML130;CID-1088438) is a <b>NOD1</b> inhibitor with an <b>IC<sub>50</sub></b> of 0.56 _M.
HYCPK548,Plate 2,A05,Inflammation Plate MCE,SP20299LPS,A10,IRAK inhibitor 2,IRAK inhibitor 2,10,m,b140266,928333-30-6,306.32,IRAK;IRAK,Free Base,OC1=CC=C(C=C1)C2=CN=C3C=CC(NCC4=CC=CO4)=NN32,10,1,IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .
HYCPK547,Plate 1,A06,Inflammation Plate MCE,SP20299LPS,A11,MCC950,MCC950,10,m,b140385,210826-40-7,404.48,NOD-like Receptor (NLR),Free Base,O=S(C1=CC(C(C)(O)C)=CO1)(NC(NC2=C3CCCC3=CC4=C2CCC4)=O)=O,11,1,"MCC950 is a potent; selective <b>NLRP3</b> inhibitor with <b>IC<sub>50</sub></b> of 7.5 nM and 8.1 nM in BMDMs and HMDMs; respectively.
HYCPK548,Plate 2,A06,Inflammation Plate MCE,SP20299LPS,A12,SC144,SC144,10,m,b144021,895158-95-9,322.3,Interleukin Related,Free Base,O=C(C1=NC=CN=C1)NNC2=NC3=C(N4C2=CC=C4)C=CC(F)=C3,12,1,"SC144 is the first-in-class orally active small-molecule gp130 inhibitor; inhibits cell growth in a panel of human ovarian cancer cell lines with IC50 values in a submicromolar range.
HYCPK547,Plate 1,A07,Inflammation Plate MCE,SP20299LPS,A13,GSK2190915,GSK2190915,10,m,b138653,936350-00-4,637.83,FLAP,Free Acid,CC(C(O)=O)(C)CC1=C(SC(C)(C)C)C2=CC(OCC3=CC=C(C)C=N3)=CC=C2N1CC4=CC=C(C5=CN=C(OCC)C=C5)C=C4,13,1,"GSK2190915(AM-803; Fiboflapon) is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM.
HYCPK548,Plate 2,A07,Inflammation Plate MCE,SP20299LPS,A14,WHI-P154,WHI-P154,10,m,b140487,211555-04-3,376.2,JAK;JAK;JAK;EGFR;EGFR,Free Base,OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1Br,14,1,"WHI-P154 is a potent <b>EGFR</b> inhibitor; and also modestly blocks <b>JAK3</b>; with <b>IC<sub>50</sub></b>s of 4 nM and 1.8 _M; respectively.
HYCPK547,Plate 1,A08,Inflammation Plate MCE,SP20299LPS,A15,WYE-354,WYE-354,10,m,b141496,1062169-56-5,495.53,mTOR;Autophagy,Free Base,COC(NC1=CC=C(C=C1)C2=NC3=C(C(N4CCOCC4)=N2)C=NN3C5CCN(CC5)C(OC)=O)=O,15,1,"WYE-354 is an ATP-competitive <b>mTOR</b> inhibitor with an <b>IC<sub>50</sub></b> of 5 nM. WYE-354 also inhibits PI3K_ and PI3K_ with IC<sub>50</sub>s of 1.89 _M  and 7.37 _M; respectively.
HYCPK548,Plate 2,A08,Inflammation Plate MCE,SP20299LPS,A16,Bendazol,Bendazol,10,m,b141502,621-72-7,208.26,NO Synthase,Free Base,C1(CC2=CC=CC=C2)=NC3=CC=CC=C3N1,16,1,"Bendazol is a hypotensive drug which can also enhance <b>NO synthase</b> activity in renal glomeruli and collecting tubules.
HYCPK547,Plate 1,A09,Inflammation Plate MCE,SP20299LPS,A17,IRAK inhibitor 6,IRAK inhibitor 6,10,m,b141451,1042672-97-8,396.46,IRAK;IRAK,Free Base,COC1=CC(N2CCOCC2)=CC=C1NC(C3=CSC(C4=CC=CN=C4)=N3)=O,17,1,"IRAK inhibitor 6 is an inhibitor of <b>interleukin-1 receptor associated kinase 4 (IRAK-4)</b> with <b>IC<sub>50</sub></b> of 160 nM.
HYCPK548,Plate 2,A09,Inflammation Plate MCE,SP20299LPS,A18,LY2409881,LY2409881,10,m,b139581,946518-61-2,485.04,IKK,Free Base,O=C(C1=C(C=C(C2=NC(NCCCN3CCN(C)CC3)=NC=C2Cl)S4)C4=CC=C1)NC5CC5,18,1,"LY2409881 is a selectivr I_B kinase _ (<b>IKK2</b>) inhibitor with an <b>IC<sub>50</sub></b> of 30 nM.
HYCPK547,Plate 1,A10,Inflammation Plate MCE,SP20299LPS,A19,SNS-062,SNS-062,10,m,b142027,1270014-40-8,384.86,Itk;Btk,Free Base,O=C(NC1CN(C2=C3C(NC=C3)=NC=N2)CCC1)CNC4=CC=CC(Cl)=C4,19,1,"SNS-062 is a potent; noncovalent <b>BTK</b> and <b>ITK</b> inhibitor; with <b>K<sub>d</sub></b> of 0.3 nM and 2.2 nM; respectively; with <b>IC<sub>50</sub></b> of 24 nM for ITK.
HYCPK548,Plate 2,A10,Inflammation Plate MCE,SP20299LPS,A20,IRAK inhibitor 1,IRAK inhibitor 1,10,m,b143634,1042224-63-4,293.37,IRAK;IRAK,Free Base,C1(C2=CN=C3N2C=CC=C3)=CC=CC(NC4CCNCC4)=N1,20,1,"IRAK inhibitor 1 is a potent <b>IRAK-4</b> inhibitor with <b>IC<sub>50</sub></b> of 216 nM; is poorly active against JNK-1 and JNK-2 with <b>IC<sub>50</sub></b> of 3.801 _M; and >10 _M; respectively.
HYCPK547,Plate 1,A11,Inflammation Plate MCE,SP20299LPS,A21,GDC-0853,GDC-0853,10,m,b139379,1434048-34-6,664.8,Btk,Free Base,O=C1C(NC(C=C2)=NC=C2N3CCN(C4COC4)C[C@@H]3C)=CC(C5=CC=NC(N6C(C7=CC(CC(C)(C)C8)=C8N7CC6)=O)=C5CO)=CN1C,21,1,"GDC-0853 is a potent and orally BTK inhibitor.
HYCPK548,Plate 2,A11,Inflammation Plate MCE,SP20299LPS,A22,AZD8186,AZD8186,10,m,b152514,1627494-13-6,457.47,PI3K,Free Base,O=C(C1=CC([C@H](NC2=CC(F)=CC(F)=C2)C)=C3C(C(C=C(N4CCOCC4)O3)=O)=C1)N(C)C,22,1,"AZD8186 is a <b>PI3K</b> inhibitor; which potently inhibits PI3K_ (IC<sub>50</sub>=4 nM) and PI3K_ (IC50<sub>50</sub>=12 nM) with selectivity over PI3K_ (IC<sub>50</sub>=35 nM) and PI3K_ (IC<sub>50</sub>=675 nM). 
HYCPK547 1:5 Dilution,Plate 3,A01,Inflammation Plate MCE,SP20299LPS,B01,DMSO_B01,DMSO_B01,-1,m,,,,,,,1,2
HYCPK548 1:5 Dilution,Plate 4,A01,Inflammation Plate MCE,SP20299LPS,B02,DMSO_B02,DMSO_B02,-1,m,,,,,,,2,2
HYCPK547 1:5 Dilution,Plate 3,A02,Inflammation Plate MCE,SP20299LPS,B03,SCH 527123,SCH 527123,2,m,b137716,473727-83-2,397.42,CXCR;CXCR,Free Base,O=C1C(C(NC2=CC=CC(C(N(C)C)=O)=C2O)=C1N[C@H](CC)C3=CC=C(O3)C)=O,3,2,"SCH 527123 is a potent; allosteric antagonist of both <b>CXCR1</b> and <b>CXCR2</b>; with <b>IC<sub>50</sub></b> values of 1000 nM and 3-6 nM; respectivelly.
HYCPK548 1:5 Dilution,Plate 4,A02,Inflammation Plate MCE,SP20299LPS,B04,Homoharringtonine,Homoharringtonine,2,m,b133222,26833-87-4,545.62,STAT;STAT,Free Base,[H][C@@]12[C@](CCC3)(C=C(OC)[C@]2(OC([C@](CCCC(O)(C)C)(O)CC(OC)=O)=O)[H])N3CCC4=CC5=C(OCO5)C=C14,4,2,"Homoharringtonine is a cytotoxic alkaloid; induces apoptosis and inhibits <b>STAT3</b> via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
HYCPK547 1:5 Dilution,Plate 3,A03,Inflammation Plate MCE,SP20299LPS,B05,K145 (hydrochloride),K145 (hydrochloride),2,m,b134853,1449240-68-9,384.92,SPHK,Hydrochloride,O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2.[H]Cl,5,2,"K145 is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 _M ; while no inhibition of SphK1 at concentrations up to 10 _M.
HYCPK548 1:5 Dilution,Plate 4,A03,Inflammation Plate MCE,SP20299LPS,B06,Pemirolast (potassium),Pemirolast (potassium),2,m,b145332,100299-08-9,266.3,Histamine Receptor;Histamine Receptor,Potassium,O=C1C(C2=N[N-]N=N2)=CN=C3N1C=CC=C3C.[K+],6,2,"Pemirolast Potassium (BMY 26517) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent.
HYCPK547 1:5 Dilution,Plate 3,A04,Inflammation Plate MCE,SP20299LPS,B07,Amlexanox,Amlexanox,2,m,b141711,68302-57-8,298.29,IKK,Free Acid,O=C(C1=C(N)N=C2C(C(C3=CC(C(C)C)=CC=C3O2)=O)=C1)O,7,2,"AmLexanox is a specific inhibitor of <b>IKK_</b> and <b>TBK1</b>; and inhibits the IKK_ and TBK1 activity determined by MBP phosphorylation with an <b>IC<sub>50</sub></b> of approximately 1-2 _M.
HYCPK548 1:5 Dilution,Plate 4,A04,Inflammation Plate MCE,SP20299LPS,B08,Solcitinib,Solcitinib,2,m,b138845,1206163-45-2,389.45,JAK;JAK;JAK,Free Base,O=C(C1CC1)NC2=NN3C(C4=CC=C(C(N5CC(C)(C)C5)=O)C=C4)=CC=CC3=N2,8,2,"Solcitinib is an orally active; competitive; potent; selective <b>JAK1</b> inhibitor; with an <b>IC<sub>50</sub></b> of 9.8 nM; and 11-; 55- and 23-fold selectivity over JAK2; JAK3 and TYK2; respectively; used in the research of moderate-to-severe plaque-type psoriasis.
HYCPK547 1:5 Dilution,Plate 3,A05,Inflammation Plate MCE,SP20299LPS,B09,Nodinitib-1,Nodinitib-1,2,m,b141503,799264-47-4,287.34,NOD-like Receptor (NLR),Free Base,NC1=NC2=CC=CC=C2N1S(=O)(C3=CC=C(C)C=C3)=O,9,2,"Nodinitib-1 (ML130;CID-1088438) is a <b>NOD1</b> inhibitor with an <b>IC<sub>50</sub></b> of 0.56 _M.
HYCPK548 1:5 Dilution,Plate 4,A05,Inflammation Plate MCE,SP20299LPS,B10,IRAK inhibitor 2,IRAK inhibitor 2,2,m,b140266,928333-30-6,306.32,IRAK;IRAK,Free Base,OC1=CC=C(C=C1)C2=CN=C3C=CC(NCC4=CC=CO4)=NN32,10,2,IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .
HYCPK547 1:5 Dilution,Plate 3,A06,Inflammation Plate MCE,SP20299LPS,B11,MCC950,MCC950,2,m,b140385,210826-40-7,404.48,NOD-like Receptor (NLR),Free Base,O=S(C1=CC(C(C)(O)C)=CO1)(NC(NC2=C3CCCC3=CC4=C2CCC4)=O)=O,11,2,"MCC950 is a potent; selective <b>NLRP3</b> inhibitor with <b>IC<sub>50</sub></b> of 7.5 nM and 8.1 nM in BMDMs and HMDMs; respectively.
HYCPK548 1:5 Dilution,Plate 4,A06,Inflammation Plate MCE,SP20299LPS,B12,SC144,SC144,2,m,b144021,895158-95-9,322.3,Interleukin Related,Free Base,O=C(C1=NC=CN=C1)NNC2=NC3=C(N4C2=CC=C4)C=CC(F)=C3,12,2,"SC144 is the first-in-class orally active small-molecule gp130 inhibitor; inhibits cell growth in a panel of human ovarian cancer cell lines with IC50 values in a submicromolar range.
HYCPK547 1:5 Dilution,Plate 3,A07,Inflammation Plate MCE,SP20299LPS,B13,GSK2190915,GSK2190915,2,m,b138653,936350-00-4,637.83,FLAP,Free Acid,CC(C(O)=O)(C)CC1=C(SC(C)(C)C)C2=CC(OCC3=CC=C(C)C=N3)=CC=C2N1CC4=CC=C(C5=CN=C(OCC)C=C5)C=C4,13,2,"GSK2190915(AM-803; Fiboflapon) is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM.
HYCPK548 1:5 Dilution,Plate 4,A07,Inflammation Plate MCE,SP20299LPS,B14,WHI-P154,WHI-P154,2,m,b140487,211555-04-3,376.2,JAK;JAK;JAK;EGFR;EGFR,Free Base,OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1Br,14,2,"WHI-P154 is a potent <b>EGFR</b> inhibitor; and also modestly blocks <b>JAK3</b>; with <b>IC<sub>50</sub></b>s of 4 nM and 1.8 _M; respectively.
HYCPK547 1:5 Dilution,Plate 3,A08,Inflammation Plate MCE,SP20299LPS,B15,WYE-354,WYE-354,2,m,b141496,1062169-56-5,495.53,mTOR;Autophagy,Free Base,COC(NC1=CC=C(C=C1)C2=NC3=C(C(N4CCOCC4)=N2)C=NN3C5CCN(CC5)C(OC)=O)=O,15,2,"WYE-354 is an ATP-competitive <b>mTOR</b> inhibitor with an <b>IC<sub>50</sub></b> of 5 nM. WYE-354 also inhibits PI3K_ and PI3K_ with IC<sub>50</sub>s of 1.89 _M  and 7.37 _M; respectively.
HYCPK548 1:5 Dilution,Plate 4,A08,Inflammation Plate MCE,SP20299LPS,B16,Bendazol,Bendazol,2,m,b141502,621-72-7,208.26,NO Synthase,Free Base,C1(CC2=CC=CC=C2)=NC3=CC=CC=C3N1,16,2,"Bendazol is a hypotensive drug which can also enhance <b>NO synthase</b> activity in renal glomeruli and collecting tubules.
HYCPK547 1:5 Dilution,Plate 3,A09,Inflammation Plate MCE,SP20299LPS,B17,IRAK inhibitor 6,IRAK inhibitor 6,2,m,b141451,1042672-97-8,396.46,IRAK;IRAK,Free Base,COC1=CC(N2CCOCC2)=CC=C1NC(C3=CSC(C4=CC=CN=C4)=N3)=O,17,2,"IRAK inhibitor 6 is an inhibitor of <b>interleukin-1 receptor associated kinase 4 (IRAK-4)</b> with <b>IC<sub>50</sub></b> of 160 nM.
HYCPK548 1:5 Dilution,Plate 4,A09,Inflammation Plate MCE,SP20299LPS,B18,LY2409881,LY2409881,2,m,b139581,946518-61-2,485.04,IKK,Free Base,O=C(C1=C(C=C(C2=NC(NCCCN3CCN(C)CC3)=NC=C2Cl)S4)C4=CC=C1)NC5CC5,18,2,"LY2409881 is a selectivr I_B kinase _ (<b>IKK2</b>) inhibitor with an <b>IC<sub>50</sub></b> of 30 nM.
HYCPK547 1:5 Dilution,Plate 3,A10,Inflammation Plate MCE,SP20299LPS,B19,SNS-062,SNS-062,2,m,b142027,1270014-40-8,384.86,Itk;Btk,Free Base,O=C(NC1CN(C2=C3C(NC=C3)=NC=N2)CCC1)CNC4=CC=CC(Cl)=C4,19,2,"SNS-062 is a potent; noncovalent <b>BTK</b> and <b>ITK</b> inhibitor; with <b>K<sub>d</sub></b> of 0.3 nM and 2.2 nM; respectively; with <b>IC<sub>50</sub></b> of 24 nM for ITK.
HYCPK548 1:5 Dilution,Plate 4,A10,Inflammation Plate MCE,SP20299LPS,B20,IRAK inhibitor 1,IRAK inhibitor 1,2,m,b143634,1042224-63-4,293.37,IRAK;IRAK,Free Base,C1(C2=CN=C3N2C=CC=C3)=CC=CC(NC4CCNCC4)=N1,20,2,"IRAK inhibitor 1 is a potent <b>IRAK-4</b> inhibitor with <b>IC<sub>50</sub></b> of 216 nM; is poorly active against JNK-1 and JNK-2 with <b>IC<sub>50</sub></b> of 3.801 _M; and >10 _M; respectively.
HYCPK547 1:5 Dilution,Plate 3,A11,Inflammation Plate MCE,SP20299LPS,B21,GDC-0853,GDC-0853,2,m,b139379,1434048-34-6,664.8,Btk,Free Base,O=C1C(NC(C=C2)=NC=C2N3CCN(C4COC4)C[C@@H]3C)=CC(C5=CC=NC(N6C(C7=CC(CC(C)(C)C8)=C8N7CC6)=O)=C5CO)=CN1C,21,2,"GDC-0853 is a potent and orally BTK inhibitor.
HYCPK548 1:5 Dilution,Plate 4,A11,Inflammation Plate MCE,SP20299LPS,B22,AZD8186,AZD8186,2,m,b152514,1627494-13-6,457.47,PI3K,Free Base,O=C(C1=CC([C@H](NC2=CC(F)=CC(F)=C2)C)=C3C(C(C=C(N4CCOCC4)O3)=O)=C1)N(C)C,22,2,"AZD8186 is a <b>PI3K</b> inhibitor; which potently inhibits PI3K_ (IC<sub>50</sub>=4 nM) and PI3K_ (IC50<sub>50</sub>=12 nM) with selectivity over PI3K_ (IC<sub>50</sub>=35 nM) and PI3K_ (IC<sub>50</sub>=675 nM). 
HYCPK547,Plate 1,B01,Inflammation Plate MCE,SP20299LPS,C01,DMSO_C01,DMSO_C01,-1,m,,,,,,,1,3
HYCPK548,Plate 2,B01,Inflammation Plate MCE,SP20299LPS,C02,DMSO_C02,DMSO_C02,-1,m,,,,,,,2,3
HYCPK547,Plate 1,B02,Inflammation Plate MCE,SP20299LPS,C03,MK-886,MK-886,10,m,b145496,118414-82-7,472.08,FLAP,Free Acid,CC(C)C1=CC=C(N(CC2=CC=C(Cl)C=C2)C(CC(C)(C(O)=O)C)=C3SC(C)(C)C)C3=C1,3,3,"MK886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) also a non-competitive inhibitor of PPAR alpha. a potent inhibitor of leukotriene (LT) biosynthesis in intact human polymorphonuclear leukocytes with IC 50 of 2.5 nM. Block the synthessis of leukotrien intact activate leukocyte.
HYCPK548,Plate 2,B02,Inflammation Plate MCE,SP20299LPS,C04,Vidofludimus,Vidofludimus,10,m,b134826,717824-30-1,355.36,Interleukin Related,Free Acid,O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O,4,3,"Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
HYCPK547,Plate 1,B03,Inflammation Plate MCE,SP20299LPS,C05,L-NAME (hydrochloride),L-NAME (hydrochloride),10,m,b133929,51298-62-5,269.69,NO Synthase,Hydrochloride,N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl,5,3,"L-NAME hydrochloride inhibits <b>NOS</b> with an <b>IC<sub>50</sub></b> of 70 _M. L-NAME is a precursor to <b>NOS</b> inhibitor L-NOARG which has an <b>IC<sub>50</sub></b> value of 1.4 _M.
HYCPK548,Plate 2,B03,Inflammation Plate MCE,SP20299LPS,C06,GS-9620,GS-9620,10,m,b141446,1228585-88-3,410.51,Toll-like Receptor (TLR),Free Base,O=C1NC2=C(N)N=C(OCCCC)N=C2N(CC3=CC=CC(CN4CCCC4)=C3)C1,6,3,"GS-9620 is a potent and selective orally active agonist of <b>Toll-Like Receptor (TLR)7</b>.
HYCPK547,Plate 1,B04,Inflammation Plate MCE,SP20299LPS,C07,Ketoprofen,Ketoprofen,10,m,b134680,22071-15-4,254.28,COX,Free Acid,O=C(C1=CC=CC=C1)C2=CC=CC(C(C(O)=O)C)=C2,7,3,"Ketoprofen (Actron) is a non-selective NSAID with IC50 of 0.5 _M and 2.33 _M for human recombinant COX-1 and COX-2; respectively.
HYCPK548,Plate 2,B04,Inflammation Plate MCE,SP20299LPS,C08,Piceatannol,Piceatannol,10,m,b142517,10083-24-6,244.24,Autophagy;Syk,Free Base,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O,8,3,"Piceatannol is a selective inhibitor of protein tyrosine kinase Syk. It  could inhibit ICa;L; Ito; IKr; Ca2+ transients and Na+-Ca2+ exchange except IK1. Shows multiple biological activities such as anti-inflammatory; antiproliferative and immunomodulatory effects.
HYCPK547,Plate 1,B05,Inflammation Plate MCE,SP20299LPS,C09,MSX-122,MSX-122,10,m,b139751,897657-95-3,292.34,CXCR;CXCR,Free Base,C1(CNC2=NC=CC=N2)=CC=C(CNC3=NC=CC=N3)C=C1,9,3,"MSX-122 is a novel small molecule and partial CXCR4 antagonist;  with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM).
HYCPK548,Plate 2,B05,Inflammation Plate MCE,SP20299LPS,C10,Flurbiprofen,Flurbiprofen,10,m,b136683,5104-49-4,244.26,PGE synthase,Free Acid,FC1=C(C2=CC=CC=C2)C=CC(C(C)C(O)=O)=C1,10,3,"Flurbiprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.
HYCPK547,Plate 1,B06,Inflammation Plate MCE,SP20299LPS,C11,LFM-A13,LFM-A13,10,m,b142223,244240-24-2,360,Btk;Polo-like Kinase (PLK);JAK;JAK;JAK,Free Base,BrC1=C(NC(/C(C#N)=C(C)\O)=O)C=C(Br)C=C1,11,3,"LFM-A13 is a potent <b>BTK</b>; <b>JAK2</b>; <b>PLK</b> inhibitor; inhibits recombinant BTK; Plx1 and PLK3 with <b>IC<sub>50</sub></b>s of 2.5 _M; 10 _M and 61 _M; shows no effects on JAK1 and JAK3; Src family kinase HCK; EGFR and IRK.
HYCPK548,Plate 2,B06,Inflammation Plate MCE,SP20299LPS,C12,Bakuchiol,Bakuchiol,10,m,b141396,10309-37-2,256.38,p38 MAPK,Free Base,OC1=CC=C(/C=C/[C@](C)(C=C)CC/C=C(C)\C)C=C1,12,3,"Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.
HYCPK547,Plate 1,B07,Inflammation Plate MCE,SP20299LPS,C13,Carprofen,Carprofen,10,m,b133937,53716-49-7,273.71,COX,Free Acid,O=C(O)C(C)C1=CC(NC2=C3C=C(Cl)C=C2)=C3C=C1,13,3,"Carprofen reduces inflammation by inhibition of COX-2 and other sources of inflammatory prostaglandins; does not interfere with COX-1 activity.
HYCPK548,Plate 2,B07,Inflammation Plate MCE,SP20299LPS,C14,Desloratadine,Desloratadine,10,m,b136586,100643-71-8,310.82,Histamine Receptor;Histamine Receptor,Free Base,ClC1=CC=C2C(CCC3=CC=CN=C3/C2=C4CCNCC/4)=C1,14,3,"Desloratadine(Sch34117) is a potent antagonist for human histamine H1 receptor used to treat allergies.
HYCPK547,Plate 1,B08,Inflammation Plate MCE,SP20299LPS,C15,BX471,BX471,10,m,b138410,217645-70-0,434.89,CCR;CCR,Free Base,O=C(N)NC1=CC(Cl)=CC=C1OCC(N2[C@H](C)CN(CC3=CC=C(F)C=C3)CC2)=O,15,3,"BX471 is a potent; selective non-peptide <b>CCR1</b> antagonist with <b>K<sub>i</sub></b> of 1 nM for human CCR1; and exhibits 250-fold selectivity for CCR1 over CCR2; CCR5 and CXCR4.
HYCPK548,Plate 2,B08,Inflammation Plate MCE,SP20299LPS,C16,Tofacitinib (citrate),Tofacitinib (citrate),10,m,b139461,540737-29-9,504.49,JAK;JAK;JAK,Citrate,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O,16,3,"Tofacitinib citrate inhibits <b>JAK3</b> with <b>IC<sub>50</sub></b> of 1 nM while inhibiting <b>JAK2</b>; <b>JAK1</b>; Rock-II and Lck with <b>IC<sub>50</sub></b> values of 20 nM; 112 nM; 3;400 nM and 3;870 nM; respectively. 
HYCPK547,Plate 1,B09,Inflammation Plate MCE,SP20299LPS,C17,IT1t (dihydrochloride),IT1t (dihydrochloride),10,m,b148663,1092776-63-0,479.57,CXCR;CXCR,Hydrochloride,CC1(C)CN2C(CS/C(NC3CCCCC3)=N\C4CCCCC4)=CSC2=N1.[H]Cl.[H]Cl,17,3,"IT1t dihydrochloride is a potent <b>CXCR4</b> antagonist; inhibits CXCL12/CXCR4 interaction with an <b>IC<sub>50</sub></b> of 2.1 nM.
HYCPK548,Plate 2,B09,Inflammation Plate MCE,SP20299LPS,C18,Diacerein,Diacerein,10,m,b142281,13739-02-1,368.29,Interleukin Related,Free Acid,O=C(C(C=C1C2=O)=CC(OC(C)=O)=C1C(C3=C2C=CC=C3OC(C)=O)=O)O,18,3,"Diacerein; a interleukin-1 beta inhibitor; is a slow-acting medicine of the class anthraquinone used to treat joint diseases.
HYCPK547,Plate 1,B10,Inflammation Plate MCE,SP20299LPS,C19,(R)-(-)-Ibuprofen,(R)-(-)-Ibuprofen,10,m,b143806,51146-57-7,206.28,COX,Free Acid,C[C@H](C1=CC=C(CC(C)C)C=C1)C(O)=O,19,3,"(R)-(-)-Ibuprofen is the R-enantiomer of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting <b>COX-1</b> and <b>COX-2</b> with <b>IC<sub>50</sub></b> of 13 _M and 370 _M; respectively.
HYCPK548,Plate 2,B10,Inflammation Plate MCE,SP20299LPS,C20,Fevipiprant,Fevipiprant,10,m,b156693,872365-14-5,426.41,CRTH2 (GPR44);CRTH2 (GPR44);Prostaglandin Receptor,Free Acid,O=C(O)CC1=C(C)N(CC2=CC=C(S(=O)(C)=O)C=C2C(F)(F)F)C3=NC=CC=C31,20,3,"Fevipiprant(QAW039) is a selective; potent; reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood.
HYCPK547,Plate 1,B11,Inflammation Plate MCE,SP20299LPS,C21,RS 504393,RS 504393,10,m,b150296,300816-15-3,417.5,CCR;CCR,Free Base,O=C1NC2=CC=C(C)C=C2C3(CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)O1,21,3,"RS 504393 is a selective <b>CCR2</b> chemokine receptor antagonist (<b>IC<sub>50</sub></b> values are 98 nM and > 100 _M for inhibition of human recombinant CCR2b and CCR1 receptors respectively). 
HYCPK548,Plate 2,B11,Inflammation Plate MCE,SP20299LPS,C22,PRT-060318,PRT-060318,10,m,b140549,1194961-19-7,340.42,Syk,Free Base,O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(C)=C3)N,22,3,"PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase <b>Syk</b> with an <b>IC<sub>50</sub></b> of 4 nM.
HYCPK547 1:5 Dilution,Plate 3,B01,Inflammation Plate MCE,SP20299LPS,D01,DMSO_D01,DMSO_D01,-1,m,,,,,,,1,4
HYCPK548 1:5 Dilution,Plate 4,B01,Inflammation Plate MCE,SP20299LPS,D02,DMSO_D02,DMSO_D02,-1,m,,,,,,,2,4
HYCPK547 1:5 Dilution,Plate 3,B02,Inflammation Plate MCE,SP20299LPS,D03,MK-886,MK-886,2,m,b145496,118414-82-7,472.08,FLAP,Free Acid,CC(C)C1=CC=C(N(CC2=CC=C(Cl)C=C2)C(CC(C)(C(O)=O)C)=C3SC(C)(C)C)C3=C1,3,4,"MK886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) also a non-competitive inhibitor of PPAR alpha. a potent inhibitor of leukotriene (LT) biosynthesis in intact human polymorphonuclear leukocytes with IC 50 of 2.5 nM. Block the synthessis of leukotrien intact activate leukocyte.
HYCPK548 1:5 Dilution,Plate 4,B02,Inflammation Plate MCE,SP20299LPS,D04,Vidofludimus,Vidofludimus,2,m,b134826,717824-30-1,355.36,Interleukin Related,Free Acid,O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O,4,4,"Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
HYCPK547 1:5 Dilution,Plate 3,B03,Inflammation Plate MCE,SP20299LPS,D05,L-NAME (hydrochloride),L-NAME (hydrochloride),2,m,b133929,51298-62-5,269.69,NO Synthase,Hydrochloride,N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl,5,4,"L-NAME hydrochloride inhibits <b>NOS</b> with an <b>IC<sub>50</sub></b> of 70 _M. L-NAME is a precursor to <b>NOS</b> inhibitor L-NOARG which has an <b>IC<sub>50</sub></b> value of 1.4 _M.
HYCPK548 1:5 Dilution,Plate 4,B03,Inflammation Plate MCE,SP20299LPS,D06,GS-9620,GS-9620,2,m,b141446,1228585-88-3,410.51,Toll-like Receptor (TLR),Free Base,O=C1NC2=C(N)N=C(OCCCC)N=C2N(CC3=CC=CC(CN4CCCC4)=C3)C1,6,4,"GS-9620 is a potent and selective orally active agonist of <b>Toll-Like Receptor (TLR)7</b>.
HYCPK547 1:5 Dilution,Plate 3,B04,Inflammation Plate MCE,SP20299LPS,D07,Ketoprofen,Ketoprofen,2,m,b134680,22071-15-4,254.28,COX,Free Acid,O=C(C1=CC=CC=C1)C2=CC=CC(C(C(O)=O)C)=C2,7,4,"Ketoprofen (Actron) is a non-selective NSAID with IC50 of 0.5 _M and 2.33 _M for human recombinant COX-1 and COX-2; respectively.
HYCPK548 1:5 Dilution,Plate 4,B04,Inflammation Plate MCE,SP20299LPS,D08,Piceatannol,Piceatannol,2,m,b142517,10083-24-6,244.24,Autophagy;Syk,Free Base,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O,8,4,"Piceatannol is a selective inhibitor of protein tyrosine kinase Syk. It  could inhibit ICa;L; Ito; IKr; Ca2+ transients and Na+-Ca2+ exchange except IK1. Shows multiple biological activities such as anti-inflammatory; antiproliferative and immunomodulatory effects.
HYCPK547 1:5 Dilution,Plate 3,B05,Inflammation Plate MCE,SP20299LPS,D09,MSX-122,MSX-122,2,m,b139751,897657-95-3,292.34,CXCR;CXCR,Free Base,C1(CNC2=NC=CC=N2)=CC=C(CNC3=NC=CC=N3)C=C1,9,4,"MSX-122 is a novel small molecule and partial CXCR4 antagonist;  with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM).
HYCPK548 1:5 Dilution,Plate 4,B05,Inflammation Plate MCE,SP20299LPS,D10,Flurbiprofen,Flurbiprofen,2,m,b136683,5104-49-4,244.26,PGE synthase,Free Acid,FC1=C(C2=CC=CC=C2)C=CC(C(C)C(O)=O)=C1,10,4,"Flurbiprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.
HYCPK547 1:5 Dilution,Plate 3,B06,Inflammation Plate MCE,SP20299LPS,D11,LFM-A13,LFM-A13,2,m,b142223,244240-24-2,360,Btk;Polo-like Kinase (PLK);JAK;JAK;JAK,Free Base,BrC1=C(NC(/C(C#N)=C(C)\O)=O)C=C(Br)C=C1,11,4,"LFM-A13 is a potent <b>BTK</b>; <b>JAK2</b>; <b>PLK</b> inhibitor; inhibits recombinant BTK; Plx1 and PLK3 with <b>IC<sub>50</sub></b>s of 2.5 _M; 10 _M and 61 _M; shows no effects on JAK1 and JAK3; Src family kinase HCK; EGFR and IRK.
HYCPK548 1:5 Dilution,Plate 4,B06,Inflammation Plate MCE,SP20299LPS,D12,Bakuchiol,Bakuchiol,2,m,b141396,10309-37-2,256.38,p38 MAPK,Free Base,OC1=CC=C(/C=C/[C@](C)(C=C)CC/C=C(C)\C)C=C1,12,4,"Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.
HYCPK547 1:5 Dilution,Plate 3,B07,Inflammation Plate MCE,SP20299LPS,D13,Carprofen,Carprofen,2,m,b133937,53716-49-7,273.71,COX,Free Acid,O=C(O)C(C)C1=CC(NC2=C3C=C(Cl)C=C2)=C3C=C1,13,4,"Carprofen reduces inflammation by inhibition of COX-2 and other sources of inflammatory prostaglandins; does not interfere with COX-1 activity.
HYCPK548 1:5 Dilution,Plate 4,B07,Inflammation Plate MCE,SP20299LPS,D14,Desloratadine,Desloratadine,2,m,b136586,100643-71-8,310.82,Histamine Receptor;Histamine Receptor,Free Base,ClC1=CC=C2C(CCC3=CC=CN=C3/C2=C4CCNCC/4)=C1,14,4,"Desloratadine(Sch34117) is a potent antagonist for human histamine H1 receptor used to treat allergies.
HYCPK547 1:5 Dilution,Plate 3,B08,Inflammation Plate MCE,SP20299LPS,D15,BX471,BX471,2,m,b138410,217645-70-0,434.89,CCR;CCR,Free Base,O=C(N)NC1=CC(Cl)=CC=C1OCC(N2[C@H](C)CN(CC3=CC=C(F)C=C3)CC2)=O,15,4,"BX471 is a potent; selective non-peptide <b>CCR1</b> antagonist with <b>K<sub>i</sub></b> of 1 nM for human CCR1; and exhibits 250-fold selectivity for CCR1 over CCR2; CCR5 and CXCR4.
HYCPK548 1:5 Dilution,Plate 4,B08,Inflammation Plate MCE,SP20299LPS,D16,Tofacitinib (citrate),Tofacitinib (citrate),2,m,b139461,540737-29-9,504.49,JAK;JAK;JAK,Citrate,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O,16,4,"Tofacitinib citrate inhibits <b>JAK3</b> with <b>IC<sub>50</sub></b> of 1 nM while inhibiting <b>JAK2</b>; <b>JAK1</b>; Rock-II and Lck with <b>IC<sub>50</sub></b> values of 20 nM; 112 nM; 3;400 nM and 3;870 nM; respectively. 
HYCPK547 1:5 Dilution,Plate 3,B09,Inflammation Plate MCE,SP20299LPS,D17,IT1t (dihydrochloride),IT1t (dihydrochloride),2,m,b148663,1092776-63-0,479.57,CXCR;CXCR,Hydrochloride,CC1(C)CN2C(CS/C(NC3CCCCC3)=N\C4CCCCC4)=CSC2=N1.[H]Cl.[H]Cl,17,4,"IT1t dihydrochloride is a potent <b>CXCR4</b> antagonist; inhibits CXCL12/CXCR4 interaction with an <b>IC<sub>50</sub></b> of 2.1 nM.
HYCPK548 1:5 Dilution,Plate 4,B09,Inflammation Plate MCE,SP20299LPS,D18,Diacerein,Diacerein,2,m,b142281,13739-02-1,368.29,Interleukin Related,Free Acid,O=C(C(C=C1C2=O)=CC(OC(C)=O)=C1C(C3=C2C=CC=C3OC(C)=O)=O)O,18,4,"Diacerein; a interleukin-1 beta inhibitor; is a slow-acting medicine of the class anthraquinone used to treat joint diseases.
HYCPK547 1:5 Dilution,Plate 3,B10,Inflammation Plate MCE,SP20299LPS,D19,(R)-(-)-Ibuprofen,(R)-(-)-Ibuprofen,2,m,b143806,51146-57-7,206.28,COX,Free Acid,C[C@H](C1=CC=C(CC(C)C)C=C1)C(O)=O,19,4,"(R)-(-)-Ibuprofen is the R-enantiomer of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting <b>COX-1</b> and <b>COX-2</b> with <b>IC<sub>50</sub></b> of 13 _M and 370 _M; respectively.
HYCPK548 1:5 Dilution,Plate 4,B10,Inflammation Plate MCE,SP20299LPS,D20,Fevipiprant,Fevipiprant,2,m,b156693,872365-14-5,426.41,CRTH2 (GPR44);CRTH2 (GPR44);Prostaglandin Receptor,Free Acid,O=C(O)CC1=C(C)N(CC2=CC=C(S(=O)(C)=O)C=C2C(F)(F)F)C3=NC=CC=C31,20,4,"Fevipiprant(QAW039) is a selective; potent; reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood.
HYCPK547 1:5 Dilution,Plate 3,B11,Inflammation Plate MCE,SP20299LPS,D21,RS 504393,RS 504393,2,m,b150296,300816-15-3,417.5,CCR;CCR,Free Base,O=C1NC2=CC=C(C)C=C2C3(CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)O1,21,4,"RS 504393 is a selective <b>CCR2</b> chemokine receptor antagonist (<b>IC<sub>50</sub></b> values are 98 nM and > 100 _M for inhibition of human recombinant CCR2b and CCR1 receptors respectively). 
HYCPK548 1:5 Dilution,Plate 4,B11,Inflammation Plate MCE,SP20299LPS,D22,PRT-060318,PRT-060318,2,m,b140549,1194961-19-7,340.42,Syk,Free Base,O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(C)=C3)N,22,4,"PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase <b>Syk</b> with an <b>IC<sub>50</sub></b> of 4 nM.
HYCPK547,Plate 1,C01,Inflammation Plate MCE,SP20299LPS,E01,DMSO_E01,DMSO_E01,-1,m,,,,,,,1,5
HYCPK548,Plate 2,C01,Inflammation Plate MCE,SP20299LPS,E02,DMSO_E02,DMSO_E02,-1,m,,,,,,,2,5
HYCPK547,Plate 1,C02,Inflammation Plate MCE,SP20299LPS,E03,IKK 16,IKK 16,10,m,b147139,873225-46-8,483.63,LRRK2;IKK,Free Base,O=C(C1=CC=C(NC2=NC=CC(C3=CC4=CC=CC=C4S3)=N2)C=C1)N5CCC(N6CCCC6)CC5,3,5,"IKK 16 is a selective I_B kinase (<b>IKK</b>) inhibitor for <b>IKK2</b>; <b>IKK complex</b> and <b>IKK1</b> with <b>IC<sub>50</sub></b>s of 40 nM; 70 nM and 200 nM; respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (<b>LRRK2</b>) with an <b>IC<sub>50</sub></b> of 50 nM.
HYCPK548,Plate 2,C02,Inflammation Plate MCE,SP20299LPS,E04,AZD-8055,AZD-8055,10,m,b136208,1009298-09-2,465.54,mTOR;Autophagy,Free Base,OCC1=CC(C2=NC3=NC(N4CCOC[C@@H]4C)=NC(N5[C@@H](C)COCC5)=C3C=C2)=CC=C1OC,4,5,"AZD-8055 is a novel ATP-competitive inhibitor of <b>mTOR</b> kinase activity; with an <b>IC<sub>50</sub></b> of 0.8 nM. 
HYCPK547,Plate 1,C03,Inflammation Plate MCE,SP20299LPS,E05,RS102895 (hydrochloride),RS102895 (hydrochloride),10,m,b147330,1173022-16-6,426.86,CCR;CCR,Hydrochloride,[H]Cl.O=C1NC2=CC=CC=C2C3(CCN(CCC4=CC=C(C(F)(F)F)C=C4)CC3)O1,5,5,"RS102895 Hcl is a potent and specific CCR2 antagonist with binding IC50 of 360 nM; no significant inhibition on CCR1(IC50 > 17 uM).
HYCPK548,Plate 2,C03,Inflammation Plate MCE,SP20299LPS,E06,BAY 11-7085,BAY 11-7085,10,m,b133709,196309-76-9,249.33,NF-_B,Free Base,N#C/C=C/S(C(C=C1)=CC=C1C(C)(C)C)(=O)=O,6,5,"BAY 11-7085 is an inhibitor of <b>NF-_B</b> activation and phosphorylation of <b>I_B_</b>; it stabilizes I_B_ with an <b>IC<sub>50</sub></b> of 10 _M.
HYCPK547,Plate 1,C04,Inflammation Plate MCE,SP20299LPS,E07,ZK756326 (dihydrochloride),ZK756326 (dihydrochloride),10,m,b147925,1780259-94-0,429.38,CCR;CCR,Hydrochloride,OCCOCCN1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1.Cl.Cl,7,5,"ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor <b>CCR8</b>. 
HYCPK548,Plate 2,C04,Inflammation Plate MCE,SP20299LPS,E08,Suplatast (Tosilate),Suplatast (Tosilate),10,m,b138106,94055-76-2,499.64,Interleukin Related,Tosylate,C[S+](C)CCC(NC1=CC=C(C=C1)OCC(COCC)O)=O.CC2=CC=C(C=C2)S(=O)([O-])=O,8,5,"Suplatast tosilate(IPD 1151T) is a Th2 cytokine inhibitor that attenuates IL-2; IL-5 and IL-13 production and has no effect on IFN-_ production. 
HYCPK547,Plate 1,C05,Inflammation Plate MCE,SP20299LPS,E09,Nicotinamide N-oxide,Nicotinamide N-oxide,10,m,b142764,1986-81-8,138.12,CXCR;CXCR,Free Base,O=C(C1=C[N+]([O-])=CC=C1)N,9,5,"Nicotinamide N-oxide; an <i>in vivo</i> nicotinamide metabolite; is a potent; and selective antagonist of the <b>CXCR2</b> receptor. 
HYCPK548,Plate 2,C05,Inflammation Plate MCE,SP20299LPS,E10,ABT-239,ABT-239,10,m,b135519,460746-46-7,330.42,Histamine Receptor;Histamine Receptor;TRP Channel,Free Base,C[C@H]1N(CCC2=CC3=C(C=CC(C4=CC=C(C#N)C=C4)=C3)O2)CCC1,10,5,"ABT-239 is a novel; highly efficacious; non-imidazole¾class of <b>H3R</b> antagonist and a transient receptor potential vanilloid type 1 (<b>TRPV1</b>) antagonist.¾
HYCPK547,Plate 1,C06,Inflammation Plate MCE,SP20299LPS,E11,WZ811,WZ811,10,m,b138445,55778-02-4,290.36,CXCR;CXCR,Free Base,C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1,11,5,"WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
HYCPK548,Plate 2,C06,Inflammation Plate MCE,SP20299LPS,E12,TGX-221,TGX-221,10,m,b142392,663619-89-4,364.44,PI3K,Free Base,O=C1N2C(C(C(NC3=CC=CC=C3)C)=CC(C)=C2)=NC(N4CCOCC4)=C1,12,5,"TGX-221 is a potent; selective; and cell membrane permeable inhibitor of the <b>PI3K p110_</b> catalytic subunit; used for cancer treatment.
HYCPK547,Plate 1,C07,Inflammation Plate MCE,SP20299LPS,E13,Reparixin (L-lysine salt),Reparixin (L-lysine salt),10,m,b138320,266359-93-7,429.57,CXCR;CXCR,L-lysine,N[C@@H](CCCCN)C(O)=O.CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O,13,5,"Reparixin L-lysine salt is a potent and specific allosteric inhibitor of both CXCL8 receptors <b>CXCR1/2</b>; it inhibits weakly <b>CXCR2</b>-mediated cell migration (<b>IC<sub>50</sub></b>=100 nM); whereas it strongly blocks <b>CXCR1</b>-mediated chemotaxis (<b>IC<sub>50</sub></b>=1 nM).
HYCPK548,Plate 2,C07,Inflammation Plate MCE,SP20299LPS,E14,AM679,AM679,10,m,b145254,1206880-66-1,692.87,FLAP,Free Acid,O=C(C)N1C2=CC=CC=C2C[C@H]1COC3=CC=C(N(CC4=CC=C(C5=NC=C(OC)C=N5)C=C4)C(CC(C)(C(O)=O)C)=C6SC(C)(C)C)C6=C3,14,5,"AM679 is a potent and selective FLAP inhibitor with IC50s of  2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively. 
HYCPK547,Plate 1,C08,Inflammation Plate MCE,SP20299LPS,E15,SB225002,SB225002,10,m,b138131,182498-32-4,352.14,CXCR;CXCR,Free Base,O=C(NC1=CC=C([N+]([O-])=O)C=C1O)NC2=CC=CC=C2Br,15,5,"SB225002 is a potent and selective <b>CXCR2</b> antagonist with an <b>IC<sub>50</sub></b> of 22 nM.
HYCPK548,Plate 2,C08,Inflammation Plate MCE,SP20299LPS,E16,Avacopan,Avacopan,10,m,b137801,1346623-17-3,581.64,Complement System,Free Base,O=C([C@@H]1[C@H](C2=CC=C(NC3CCCC3)C=C2)N(C(C4=C(C)C=CC=C4F)=O)CCC1)NC5=CC=C(C)C(C(F)(F)F)=C5,16,5,"Avacopan (CCX168) is a potent; selective and orally available <b>complement</b> 5a receptor inhibitor with an <b>IC<sub>50</sub></b> of 0.1 nM.
HYCPK547,Plate 1,C09,Inflammation Plate MCE,SP20299LPS,E17,Naproxen,Naproxen,10,m,b142379,22204-53-1,230.26,COX;Autophagy,Free Acid,C[C@H](C(O)=O)C1=CC2=CC=C(OC)C=C2C=C1,17,5,"Naproxen is a <b>COX-1</b> and <b>COX-2</b> inhibitor with <b>IC<sub>50</sub></b>s of 2.2 and 1.3 _g/mL; respectively in cell assay.
HYCPK548,Plate 2,C09,Inflammation Plate MCE,SP20299LPS,E18,Firocoxib,Firocoxib,10,m,b141765,189954-96-9,336.4,COX,Free Base,O=C1OC(C)(C)C(C2=CC=C(S(=O)(C)=O)C=C2)=C1OCC3CC3,18,5,"Firocoxib(ML 1785713) is a potent and selective cyclooxygenase (COX)-2 inhibitor with IC50 of 0.13 uM; 58 fold sensitivity for COX2 VSCOX1.
HYCPK547,Plate 1,C10,Inflammation Plate MCE,SP20299LPS,E19,PF-4136309,PF-4136309,10,m,b134197,1341224-83-6,568.59,CCR;CCR,Free Base,O[C@]1(CC[C@](CC1)([H])N[C@@H]2CN(CC2)C(CNC(C3=CC=CC(C(F)(F)F)=C3)=O)=O)C4=NC=C(C=C4)C5=NC=CC=N5,19,5,"PF-4136309 is a potent; selective; and orally bioavailable <b>CCR2</b> antagonist; with <b>IC<sub>50</sub></b> of 5.2 nM; 17 nM and 13 nM for human; mouse and rat CCR2.
HYCPK548,Plate 2,C10,Inflammation Plate MCE,SP20299LPS,E20,TAK-715,TAK-715,10,m,b138468,303162-79-0,399.51,p38 MAPK,Free Base,O=C(C1=CC=CC=C1)NC2=NC=CC(C3=C(N=C(S3)CC)C4=CC=CC(C)=C4)=C2,20,5,"TAK-715 is a p38 MAPK inhibitor for p38_ with IC50 of 7.1 nM; 28-fold more selective for p38_ over p38_; no inhibition to p38_/_; JNK1; ERK1; IKK_; MEKK1 or TAK1.
HYCPK547,Plate 1,C11,Inflammation Plate MCE,SP20299LPS,E21,Betahistine (dihydrochloride),Betahistine (dihydrochloride),10,m,b144375,5579-84-0,209.12,Histamine Receptor;Histamine Receptor,Hydrochloride,CNCCC1=CC=CC=N1.Cl.Cl,21,5,"Betahistine Dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug.
HYCPK548,Plate 2,C11,Inflammation Plate MCE,SP20299LPS,E22,PF-06651600,PF-06651600,10,m,b135182,1792180-81-4,285.34,JAK;JAK;JAK,Free Base,C=CC(N1[C@@H](C)CC[C@@H](NC2=C3C(NC=C3)=NC=N2)C1)=O,22,5,"PF-06651600 is a potent <b>JAK3</b>-selective inhibitor with an <b>IC<sub>50</sub></b> of 33.1 nM.
HYCPK547 1:5 Dilution,Plate 3,C01,Inflammation Plate MCE,SP20299LPS,F01,DMSO_F01,DMSO_F01,-1,m,,,,,,,1,6
HYCPK548 1:5 Dilution,Plate 4,C01,Inflammation Plate MCE,SP20299LPS,F02,DMSO_F02,DMSO_F02,-1,m,,,,,,,2,6
HYCPK547 1:5 Dilution,Plate 3,C02,Inflammation Plate MCE,SP20299LPS,F03,IKK 16,IKK 16,2,m,b147139,873225-46-8,483.63,LRRK2;IKK,Free Base,O=C(C1=CC=C(NC2=NC=CC(C3=CC4=CC=CC=C4S3)=N2)C=C1)N5CCC(N6CCCC6)CC5,3,6,"IKK 16 is a selective I_B kinase (<b>IKK</b>) inhibitor for <b>IKK2</b>; <b>IKK complex</b> and <b>IKK1</b> with <b>IC<sub>50</sub></b>s of 40 nM; 70 nM and 200 nM; respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (<b>LRRK2</b>) with an <b>IC<sub>50</sub></b> of 50 nM.
HYCPK548 1:5 Dilution,Plate 4,C02,Inflammation Plate MCE,SP20299LPS,F04,AZD-8055,AZD-8055,2,m,b136208,1009298-09-2,465.54,mTOR;Autophagy,Free Base,OCC1=CC(C2=NC3=NC(N4CCOC[C@@H]4C)=NC(N5[C@@H](C)COCC5)=C3C=C2)=CC=C1OC,4,6,"AZD-8055 is a novel ATP-competitive inhibitor of <b>mTOR</b> kinase activity; with an <b>IC<sub>50</sub></b> of 0.8 nM. 
HYCPK547 1:5 Dilution,Plate 3,C03,Inflammation Plate MCE,SP20299LPS,F05,RS102895 (hydrochloride),RS102895 (hydrochloride),2,m,b147330,1173022-16-6,426.86,CCR;CCR,Hydrochloride,[H]Cl.O=C1NC2=CC=CC=C2C3(CCN(CCC4=CC=C(C(F)(F)F)C=C4)CC3)O1,5,6,"RS102895 Hcl is a potent and specific CCR2 antagonist with binding IC50 of 360 nM; no significant inhibition on CCR1(IC50 > 17 uM).
HYCPK548 1:5 Dilution,Plate 4,C03,Inflammation Plate MCE,SP20299LPS,F06,BAY 11-7085,BAY 11-7085,2,m,b133709,196309-76-9,249.33,NF-_B,Free Base,N#C/C=C/S(C(C=C1)=CC=C1C(C)(C)C)(=O)=O,6,6,"BAY 11-7085 is an inhibitor of <b>NF-_B</b> activation and phosphorylation of <b>I_B_</b>; it stabilizes I_B_ with an <b>IC<sub>50</sub></b> of 10 _M.
HYCPK547 1:5 Dilution,Plate 3,C04,Inflammation Plate MCE,SP20299LPS,F07,ZK756326 (dihydrochloride),ZK756326 (dihydrochloride),2,m,b147925,1780259-94-0,429.38,CCR;CCR,Hydrochloride,OCCOCCN1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1.Cl.Cl,7,6,"ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor <b>CCR8</b>. 
HYCPK548 1:5 Dilution,Plate 4,C04,Inflammation Plate MCE,SP20299LPS,F08,Suplatast (Tosilate),Suplatast (Tosilate),2,m,b138106,94055-76-2,499.64,Interleukin Related,Tosylate,C[S+](C)CCC(NC1=CC=C(C=C1)OCC(COCC)O)=O.CC2=CC=C(C=C2)S(=O)([O-])=O,8,6,"Suplatast tosilate(IPD 1151T) is a Th2 cytokine inhibitor that attenuates IL-2; IL-5 and IL-13 production and has no effect on IFN-_ production. 
HYCPK547 1:5 Dilution,Plate 3,C05,Inflammation Plate MCE,SP20299LPS,F09,Nicotinamide N-oxide,Nicotinamide N-oxide,2,m,b142764,1986-81-8,138.12,CXCR;CXCR,Free Base,O=C(C1=C[N+]([O-])=CC=C1)N,9,6,"Nicotinamide N-oxide; an <i>in vivo</i> nicotinamide metabolite; is a potent; and selective antagonist of the <b>CXCR2</b> receptor. 
HYCPK548 1:5 Dilution,Plate 4,C05,Inflammation Plate MCE,SP20299LPS,F10,ABT-239,ABT-239,2,m,b135519,460746-46-7,330.42,Histamine Receptor;Histamine Receptor;TRP Channel,Free Base,C[C@H]1N(CCC2=CC3=C(C=CC(C4=CC=C(C#N)C=C4)=C3)O2)CCC1,10,6,"ABT-239 is a novel; highly efficacious; non-imidazole¾class of <b>H3R</b> antagonist and a transient receptor potential vanilloid type 1 (<b>TRPV1</b>) antagonist.¾
HYCPK547 1:5 Dilution,Plate 3,C06,Inflammation Plate MCE,SP20299LPS,F11,WZ811,WZ811,2,m,b138445,55778-02-4,290.36,CXCR;CXCR,Free Base,C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1,11,6,"WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
HYCPK548 1:5 Dilution,Plate 4,C06,Inflammation Plate MCE,SP20299LPS,F12,TGX-221,TGX-221,2,m,b142392,663619-89-4,364.44,PI3K,Free Base,O=C1N2C(C(C(NC3=CC=CC=C3)C)=CC(C)=C2)=NC(N4CCOCC4)=C1,12,6,"TGX-221 is a potent; selective; and cell membrane permeable inhibitor of the <b>PI3K p110_</b> catalytic subunit; used for cancer treatment.
HYCPK547 1:5 Dilution,Plate 3,C07,Inflammation Plate MCE,SP20299LPS,F13,Reparixin (L-lysine salt),Reparixin (L-lysine salt),2,m,b138320,266359-93-7,429.57,CXCR;CXCR,L-lysine,N[C@@H](CCCCN)C(O)=O.CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O,13,6,"Reparixin L-lysine salt is a potent and specific allosteric inhibitor of both CXCL8 receptors <b>CXCR1/2</b>; it inhibits weakly <b>CXCR2</b>-mediated cell migration (<b>IC<sub>50</sub></b>=100 nM); whereas it strongly blocks <b>CXCR1</b>-mediated chemotaxis (<b>IC<sub>50</sub></b>=1 nM).
HYCPK548 1:5 Dilution,Plate 4,C07,Inflammation Plate MCE,SP20299LPS,F14,AM679,AM679,2,m,b145254,1206880-66-1,692.87,FLAP,Free Acid,O=C(C)N1C2=CC=CC=C2C[C@H]1COC3=CC=C(N(CC4=CC=C(C5=NC=C(OC)C=N5)C=C4)C(CC(C)(C(O)=O)C)=C6SC(C)(C)C)C6=C3,14,6,"AM679 is a potent and selective FLAP inhibitor with IC50s of  2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively. 
HYCPK547 1:5 Dilution,Plate 3,C08,Inflammation Plate MCE,SP20299LPS,F15,SB225002,SB225002,2,m,b138131,182498-32-4,352.14,CXCR;CXCR,Free Base,O=C(NC1=CC=C([N+]([O-])=O)C=C1O)NC2=CC=CC=C2Br,15,6,"SB225002 is a potent and selective <b>CXCR2</b> antagonist with an <b>IC<sub>50</sub></b> of 22 nM.
HYCPK548 1:5 Dilution,Plate 4,C08,Inflammation Plate MCE,SP20299LPS,F16,Avacopan,Avacopan,2,m,b137801,1346623-17-3,581.64,Complement System,Free Base,O=C([C@@H]1[C@H](C2=CC=C(NC3CCCC3)C=C2)N(C(C4=C(C)C=CC=C4F)=O)CCC1)NC5=CC=C(C)C(C(F)(F)F)=C5,16,6,"Avacopan (CCX168) is a potent; selective and orally available <b>complement</b> 5a receptor inhibitor with an <b>IC<sub>50</sub></b> of 0.1 nM.
HYCPK547 1:5 Dilution,Plate 3,C09,Inflammation Plate MCE,SP20299LPS,F17,Naproxen,Naproxen,2,m,b142379,22204-53-1,230.26,COX;Autophagy,Free Acid,C[C@H](C(O)=O)C1=CC2=CC=C(OC)C=C2C=C1,17,6,"Naproxen is a <b>COX-1</b> and <b>COX-2</b> inhibitor with <b>IC<sub>50</sub></b>s of 2.2 and 1.3 _g/mL; respectively in cell assay.
HYCPK548 1:5 Dilution,Plate 4,C09,Inflammation Plate MCE,SP20299LPS,F18,Firocoxib,Firocoxib,2,m,b141765,189954-96-9,336.4,COX,Free Base,O=C1OC(C)(C)C(C2=CC=C(S(=O)(C)=O)C=C2)=C1OCC3CC3,18,6,"Firocoxib(ML 1785713) is a potent and selective cyclooxygenase (COX)-2 inhibitor with IC50 of 0.13 uM; 58 fold sensitivity for COX2 VSCOX1.
HYCPK547 1:5 Dilution,Plate 3,C10,Inflammation Plate MCE,SP20299LPS,F19,PF-4136309,PF-4136309,2,m,b134197,1341224-83-6,568.59,CCR;CCR,Free Base,O[C@]1(CC[C@](CC1)([H])N[C@@H]2CN(CC2)C(CNC(C3=CC=CC(C(F)(F)F)=C3)=O)=O)C4=NC=C(C=C4)C5=NC=CC=N5,19,6,"PF-4136309 is a potent; selective; and orally bioavailable <b>CCR2</b> antagonist; with <b>IC<sub>50</sub></b> of 5.2 nM; 17 nM and 13 nM for human; mouse and rat CCR2.
HYCPK548 1:5 Dilution,Plate 4,C10,Inflammation Plate MCE,SP20299LPS,F20,TAK-715,TAK-715,2,m,b138468,303162-79-0,399.51,p38 MAPK,Free Base,O=C(C1=CC=CC=C1)NC2=NC=CC(C3=C(N=C(S3)CC)C4=CC=CC(C)=C4)=C2,20,6,"TAK-715 is a p38 MAPK inhibitor for p38_ with IC50 of 7.1 nM; 28-fold more selective for p38_ over p38_; no inhibition to p38_/_; JNK1; ERK1; IKK_; MEKK1 or TAK1.
HYCPK547 1:5 Dilution,Plate 3,C11,Inflammation Plate MCE,SP20299LPS,F21,Betahistine (dihydrochloride),Betahistine (dihydrochloride),2,m,b144375,5579-84-0,209.12,Histamine Receptor;Histamine Receptor,Hydrochloride,CNCCC1=CC=CC=N1.Cl.Cl,21,6,"Betahistine Dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug.
HYCPK548 1:5 Dilution,Plate 4,C11,Inflammation Plate MCE,SP20299LPS,F22,PF-06651600,PF-06651600,2,m,b135182,1792180-81-4,285.34,JAK;JAK;JAK,Free Base,C=CC(N1[C@@H](C)CC[C@@H](NC2=C3C(NC=C3)=NC=N2)C1)=O,22,6,"PF-06651600 is a potent <b>JAK3</b>-selective inhibitor with an <b>IC<sub>50</sub></b> of 33.1 nM.
HYCPK547,Plate 1,D01,Inflammation Plate MCE,SP20299LPS,G01,DMSO_G01,DMSO_G01,-1,m,,,,,,,1,7
HYCPK548,Plate 2,D01,Inflammation Plate MCE,SP20299LPS,G02,DMSO_G02,DMSO_G02,-1,m,,,,,,,2,7
HYCPK547,Plate 1,D02,Inflammation Plate MCE,SP20299LPS,G03,MF63,MF63,10,m,b139660,892549-43-8,378.81,PGE synthase,Free Base,ClC1=CC(C2=C3C=CC=C2)=C(C4=C3N=C(C5=C(C=CC=C5C#N)C#N)N4)C=C1,3,7,"MF63 is a selective mPGES-1 inhibitor with an IC50 of 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme; respectively. 
HYCPK548,Plate 2,D02,Inflammation Plate MCE,SP20299LPS,G04,SKI II,SKI II,10,m,b135089,312636-16-1,302.78,SPHK,Free Base,OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1,4,7,"SKI-II is a synthetic inhibitor of sphingosine kinase (SK) activity with IC50 of 78 _M for SK1 and 45 _M for SK2.
HYCPK547,Plate 1,D03,Inflammation Plate MCE,SP20299LPS,G05,Pranoprofen,Pranoprofen,10,m,b146086,52549-17-4,255.27,PGE synthase,Free Acid,CC(C(O)=O)C1=CC2=C(C=C1)OC3=NC=CC=C3C2,5,7,"Pranoprofen is a non-steroidal anti-inflammatory drug used in ophthalmology. 
HYCPK548,Plate 2,D03,Inflammation Plate MCE,SP20299LPS,G06,Motolimod,Motolimod,10,m,b147267,926927-61-9,458.6,Toll-like Receptor (TLR),Free Base,O=C(C1=CC2=CC=C(C3=CC=C(C(N4CCCC4)=O)C=C3)C=C2N=C(N)C1)N(CCC)CCC,6,7,"Motolimod is a selective <b>Toll-like receptor (TLR) 8</b> agonist; with <b>EC<sub>50</sub></b> of about 100 nM. 
HYCPK547,Plate 1,D04,Inflammation Plate MCE,SP20299LPS,G07,Reparixin,Reparixin,10,m,b142081,266359-83-5,283.39,CXCR;CXCR,Free Base,CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O,7,7,"Reparixin is a potent inhibitor of both CXCL8 receptors <b>CXCR1/2</b>; it inhibits weakly <b>CXCR2</b>-mediated cell migration (<b>IC<sub>50</sub></b>=100 nM); whereas it strongly blocks <b>CXCR1</b>-mediated chemotaxis (<b>IC<sub>50</sub></b>=1 nM).
HYCPK548,Plate 2,D04,Inflammation Plate MCE,SP20299LPS,G08,CAL-101,CAL-101,10,m,b133756,870281-82-6,415.42,PI3K;Autophagy,Free Base,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5,8,7,"CAL-101 is a highly selective and potent <b>p110_</b> inhibitor with <b>IC<sub>50</sub></b> of 2.5 nM; is 40- to 300-fold more selective for p110_ relative to other PI3K class I enzymes (<b>p110_</b>; <b>p110_</b>; and <b>p110_</b>; <b>IC<sub>50</sub></b> are 820; 565; and 89nM; respectively). 
HYCPK547,Plate 1,D05,Inflammation Plate MCE,SP20299LPS,G09,Acalabrutinib,Acalabrutinib,10,m,b144156,1420477-60-6,465.51,Btk,Free Base,O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2,9,7,"Acalabrutinib is a novel; potent; and highly selective <b>BTK</b> inhibitor; with an <b>IC<sub>50</sub></b> of 3 nM and <b>EC<sub>50</sub></b> of 8 nM in a human whole-blood CD69 B cell activation assay.
HYCPK548,Plate 2,D05,Inflammation Plate MCE,SP20299LPS,G10,Fingolimod,Fingolimod,10,m,b136465,162359-55-9,307.47,SPHK,Free Base,OCC(CCC1=CC=C(CCCCCCCC)C=C1)(N)CO,10,7,"Fingolimod is a <b>sphingosine 1-phosphate</b> (<b>S1P</b>) antagonist with <b>IC<sub>50</sub></b> of 0.033 nM in K562 and NK cells.
HYCPK547,Plate 1,D06,Inflammation Plate MCE,SP20299LPS,G11,Etodolac,Etodolac,10,m,b138359,41340-25-4,287.35,COX,Free Acid,O=C(O)CC(OCC1)(CC)C2=C1C3=CC=CC(CC)=C3N2,11,7,"Etodolac is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)
HYCPK548,Plate 2,D06,Inflammation Plate MCE,SP20299LPS,G12,Nifuroxazide,Nifuroxazide,10,m,b147584,965-52-6,275.22,STAT;STAT,Free Base,O=C(N/N=C/C1=CC=C([N+]([O-])=O)O1)C2=CC=C(O)C=C2,12,7,"Nifuroxazide is an inhibitor of STAT activation and signaling activity; is an oral nitrofuran antibiotic; used to treat colitis and diarrhea in humans and non-humans.
HYCPK547,Plate 1,D07,Inflammation Plate MCE,SP20299LPS,G13,Aspirin,Aspirin,10,m,b138720,50-78-2,180.16,COX;Autophagy,Free Acid,OC(C1=C(OC(C)=O)C=CC=C1)=O,13,7,"Aspirin (acetylsalicylic acid ) is an inhibitor of <b>COX-1</b> with an <b>IC<sub>50</sub></b> of 5 _g/mL; commonly used for the treatment of pain; fever; and inflammation.
HYCPK548,Plate 2,D07,Inflammation Plate MCE,SP20299LPS,G14,VUF10460,VUF10460,10,m,b144476,1028327-66-3,269.34,Histamine Receptor;Histamine Receptor,Free Base,NC1=NC(C2=CC=CC=C2)=CC(N3CCN(C)CC3)=N1,14,7,"VUF10460 is a non-imidazole histamine <b>H4</b> receptor agonist; binds to rat H4 receptor with a <b>pK<sub>i</sub></b> of 7.46.
HYCPK547,Plate 1,D08,Inflammation Plate MCE,SP20299LPS,G15,Leukadherin-1,Leukadherin-1,10,m,b137439,344897-95-6,421.49,Complement System,Free Acid,O=C(O)C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1,15,7,"Leukadherin-1 is a specific agonist of <b>CR3</b> and the leukocyte surface integrin CD11b/CD18. 
HYCPK548,Plate 2,D08,Inflammation Plate MCE,SP20299LPS,G16,Toll-like receptor modulator,Toll-like receptor modulator,10,m,b145839,926927-42-6,348.27,Toll-like Receptor (TLR),Free Base,O=C(C1=CC2=CC=C(C(F)(C(F)(F)F)F)C=C2N=C(C1)N)OCC,16,7,A Toll-like receptor modulator.
HYCPK547,Plate 1,D09,Inflammation Plate MCE,SP20299LPS,G17,Clemastine (fumarate),Clemastine (fumarate),10,m,b139455,14976-57-9,459.96,Histamine Receptor;Histamine Receptor;Autophagy,Fumarate,CN1[C@@H](CCO[C@](C2=CC=CC=C2)(C3=CC=C(Cl)C=C3)C)CCC1.O=C(O)/C=C/C(O)=O,17,7,"Clemastine Fumarate is a selective histamine H1 receptor antagonist with IC50 of 3 nM.
HYCPK548,Plate 2,D09,Inflammation Plate MCE,SP20299LPS,G18,Cerdulatinib,Cerdulatinib,10,m,b134695,1198300-79-6,445.54,JAK;JAK;JAK;Syk,Free Base,O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O,18,7,"Cerdulatinib is a novel; orally available; ATP-competitive <b>JAK</b> and <b>SYK</b> inhibitor that demonstrates selective inhibition of TYK2 and SYK with an <b>IC<sub>50</sub></b> of 0.5 nM and 32 nM.
HYCPK547,Plate 1,D10,Inflammation Plate MCE,SP20299LPS,G19,AZD1981,AZD1981,10,m,b138974,802904-66-1,388.87,CRTH2 (GPR44);CRTH2 (GPR44);Prostaglandin Receptor,Free Acid,O=C(O)CN1C(C)=C(SC2=CC=C(Cl)C=C2)C3=C1C=CC=C3NC(C)=O,19,7,"AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4).
HYCPK548,Plate 2,D10,Inflammation Plate MCE,SP20299LPS,G20,CCCP,CCCP,10,m,b147368,555-60-2,204.62,IFNAR;STING,Free Base,N#C/C(C#N)=N/NC1=CC=CC(Cl)=C1,20,7,"CCCP inhibits STING-mediated <b>IFN-_</b> production via disrupting mitochondrial membrane potential (MMP). CCCP inhibits activation of <b>STING</b> and its downstream signaling molecules; TBK1 and IRF3.
HYCPK547,Plate 1,D11,Inflammation Plate MCE,SP20299LPS,G21,Indirubin-3'-monoxime,Indirubin-3'-monoxime,10,m,b139456,160807-49-8,277.28,GSK-3;GSK-3;5-Lipoxygenase,Free Base,O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=N/O,21,7,"Indirubin-3'-monoxime is a potent <b>GSK-3_</b> inhibitor; and a less potent inhibitor of <b>5-Lipoxygenase</b>; with <b>IC<sub>50</sub></b>s of 22 nM and 7.8-10 µM; respectively; also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B; with <b>IC<sub>50</sub></b>s of 100 and 180 nM.
HYCPK548,Plate 2,D11,Inflammation Plate MCE,SP20299LPS,G22,PD 169316,PD 169316,10,m,b133377,152121-53-4,360.34,p38 MAPK;Autophagy,Free Base,FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=C([N+]([O-])=O)C=C4)=N2,22,7,"PD 169316 is a potent; cell-permeable and selective <b>p38 MAP kinase</b> inhibitor; with <b>IC<sub>50</sub></b> of 89 nM.
HYCPK547 1:5 Dilution,Plate 3,D01,Inflammation Plate MCE,SP20299LPS,H01,DMSO_H01,DMSO_H01,-1,m,,,,,,,1,8
HYCPK548 1:5 Dilution,Plate 4,D01,Inflammation Plate MCE,SP20299LPS,H02,DMSO_H02,DMSO_H02,-1,m,,,,,,,2,8
HYCPK547 1:5 Dilution,Plate 3,D02,Inflammation Plate MCE,SP20299LPS,H03,MF63,MF63,2,m,b139660,892549-43-8,378.81,PGE synthase,Free Base,ClC1=CC(C2=C3C=CC=C2)=C(C4=C3N=C(C5=C(C=CC=C5C#N)C#N)N4)C=C1,3,8,"MF63 is a selective mPGES-1 inhibitor with an IC50 of 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme; respectively. 
HYCPK548 1:5 Dilution,Plate 4,D02,Inflammation Plate MCE,SP20299LPS,H04,SKI II,SKI II,2,m,b135089,312636-16-1,302.78,SPHK,Free Base,OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1,4,8,"SKI-II is a synthetic inhibitor of sphingosine kinase (SK) activity with IC50 of 78 _M for SK1 and 45 _M for SK2.
HYCPK547 1:5 Dilution,Plate 3,D03,Inflammation Plate MCE,SP20299LPS,H05,Pranoprofen,Pranoprofen,2,m,b146086,52549-17-4,255.27,PGE synthase,Free Acid,CC(C(O)=O)C1=CC2=C(C=C1)OC3=NC=CC=C3C2,5,8,"Pranoprofen is a non-steroidal anti-inflammatory drug used in ophthalmology. 
HYCPK548 1:5 Dilution,Plate 4,D03,Inflammation Plate MCE,SP20299LPS,H06,Motolimod,Motolimod,2,m,b147267,926927-61-9,458.6,Toll-like Receptor (TLR),Free Base,O=C(C1=CC2=CC=C(C3=CC=C(C(N4CCCC4)=O)C=C3)C=C2N=C(N)C1)N(CCC)CCC,6,8,"Motolimod is a selective <b>Toll-like receptor (TLR) 8</b> agonist; with <b>EC<sub>50</sub></b> of about 100 nM. 
HYCPK547 1:5 Dilution,Plate 3,D04,Inflammation Plate MCE,SP20299LPS,H07,Reparixin,Reparixin,2,m,b142081,266359-83-5,283.39,CXCR;CXCR,Free Base,CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O,7,8,"Reparixin is a potent inhibitor of both CXCL8 receptors <b>CXCR1/2</b>; it inhibits weakly <b>CXCR2</b>-mediated cell migration (<b>IC<sub>50</sub></b>=100 nM); whereas it strongly blocks <b>CXCR1</b>-mediated chemotaxis (<b>IC<sub>50</sub></b>=1 nM).
HYCPK548 1:5 Dilution,Plate 4,D04,Inflammation Plate MCE,SP20299LPS,H08,CAL-101,CAL-101,2,m,b133756,870281-82-6,415.42,PI3K;Autophagy,Free Base,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5,8,8,"CAL-101 is a highly selective and potent <b>p110_</b> inhibitor with <b>IC<sub>50</sub></b> of 2.5 nM; is 40- to 300-fold more selective for p110_ relative to other PI3K class I enzymes (<b>p110_</b>; <b>p110_</b>; and <b>p110_</b>; <b>IC<sub>50</sub></b> are 820; 565; and 89nM; respectively). 
HYCPK547 1:5 Dilution,Plate 3,D05,Inflammation Plate MCE,SP20299LPS,H09,Acalabrutinib,Acalabrutinib,2,m,b144156,1420477-60-6,465.51,Btk,Free Base,O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2,9,8,"Acalabrutinib is a novel; potent; and highly selective <b>BTK</b> inhibitor; with an <b>IC<sub>50</sub></b> of 3 nM and <b>EC<sub>50</sub></b> of 8 nM in a human whole-blood CD69 B cell activation assay.
HYCPK548 1:5 Dilution,Plate 4,D05,Inflammation Plate MCE,SP20299LPS,H10,Fingolimod,Fingolimod,2,m,b136465,162359-55-9,307.47,SPHK,Free Base,OCC(CCC1=CC=C(CCCCCCCC)C=C1)(N)CO,10,8,"Fingolimod is a <b>sphingosine 1-phosphate</b> (<b>S1P</b>) antagonist with <b>IC<sub>50</sub></b> of 0.033 nM in K562 and NK cells.
HYCPK547 1:5 Dilution,Plate 3,D06,Inflammation Plate MCE,SP20299LPS,H11,Etodolac,Etodolac,2,m,b138359,41340-25-4,287.35,COX,Free Acid,O=C(O)CC(OCC1)(CC)C2=C1C3=CC=CC(CC)=C3N2,11,8,"Etodolac is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)
HYCPK548 1:5 Dilution,Plate 4,D06,Inflammation Plate MCE,SP20299LPS,H12,Nifuroxazide,Nifuroxazide,2,m,b147584,965-52-6,275.22,STAT;STAT,Free Base,O=C(N/N=C/C1=CC=C([N+]([O-])=O)O1)C2=CC=C(O)C=C2,12,8,"Nifuroxazide is an inhibitor of STAT activation and signaling activity; is an oral nitrofuran antibiotic; used to treat colitis and diarrhea in humans and non-humans.
HYCPK547 1:5 Dilution,Plate 3,D07,Inflammation Plate MCE,SP20299LPS,H13,Aspirin,Aspirin,2,m,b138720,50-78-2,180.16,COX;Autophagy,Free Acid,OC(C1=C(OC(C)=O)C=CC=C1)=O,13,8,"Aspirin (acetylsalicylic acid ) is an inhibitor of <b>COX-1</b> with an <b>IC<sub>50</sub></b> of 5 _g/mL; commonly used for the treatment of pain; fever; and inflammation.
HYCPK548 1:5 Dilution,Plate 4,D07,Inflammation Plate MCE,SP20299LPS,H14,VUF10460,VUF10460,2,m,b144476,1028327-66-3,269.34,Histamine Receptor;Histamine Receptor,Free Base,NC1=NC(C2=CC=CC=C2)=CC(N3CCN(C)CC3)=N1,14,8,"VUF10460 is a non-imidazole histamine <b>H4</b> receptor agonist; binds to rat H4 receptor with a <b>pK<sub>i</sub></b> of 7.46.
HYCPK547 1:5 Dilution,Plate 3,D08,Inflammation Plate MCE,SP20299LPS,H15,Leukadherin-1,Leukadherin-1,2,m,b137439,344897-95-6,421.49,Complement System,Free Acid,O=C(O)C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1,15,8,"Leukadherin-1 is a specific agonist of <b>CR3</b> and the leukocyte surface integrin CD11b/CD18. 
HYCPK548 1:5 Dilution,Plate 4,D08,Inflammation Plate MCE,SP20299LPS,H16,Toll-like receptor modulator,Toll-like receptor modulator,2,m,b145839,926927-42-6,348.27,Toll-like Receptor (TLR),Free Base,O=C(C1=CC2=CC=C(C(F)(C(F)(F)F)F)C=C2N=C(C1)N)OCC,16,8,A Toll-like receptor modulator.
HYCPK547 1:5 Dilution,Plate 3,D09,Inflammation Plate MCE,SP20299LPS,H17,Clemastine (fumarate),Clemastine (fumarate),2,m,b139455,14976-57-9,459.96,Histamine Receptor;Histamine Receptor;Autophagy,Fumarate,CN1[C@@H](CCO[C@](C2=CC=CC=C2)(C3=CC=C(Cl)C=C3)C)CCC1.O=C(O)/C=C/C(O)=O,17,8,"Clemastine Fumarate is a selective histamine H1 receptor antagonist with IC50 of 3 nM.
HYCPK548 1:5 Dilution,Plate 4,D09,Inflammation Plate MCE,SP20299LPS,H18,Cerdulatinib,Cerdulatinib,2,m,b134695,1198300-79-6,445.54,JAK;JAK;JAK;Syk,Free Base,O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O,18,8,"Cerdulatinib is a novel; orally available; ATP-competitive <b>JAK</b> and <b>SYK</b> inhibitor that demonstrates selective inhibition of TYK2 and SYK with an <b>IC<sub>50</sub></b> of 0.5 nM and 32 nM.
HYCPK547 1:5 Dilution,Plate 3,D10,Inflammation Plate MCE,SP20299LPS,H19,AZD1981,AZD1981,2,m,b138974,802904-66-1,388.87,CRTH2 (GPR44);CRTH2 (GPR44);Prostaglandin Receptor,Free Acid,O=C(O)CN1C(C)=C(SC2=CC=C(Cl)C=C2)C3=C1C=CC=C3NC(C)=O,19,8,"AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4).
HYCPK548 1:5 Dilution,Plate 4,D10,Inflammation Plate MCE,SP20299LPS,H20,CCCP,CCCP,2,m,b147368,555-60-2,204.62,IFNAR;STING,Free Base,N#C/C(C#N)=N/NC1=CC=CC(Cl)=C1,20,8,"CCCP inhibits STING-mediated <b>IFN-_</b> production via disrupting mitochondrial membrane potential (MMP). CCCP inhibits activation of <b>STING</b> and its downstream signaling molecules; TBK1 and IRF3.
HYCPK547 1:5 Dilution,Plate 3,D11,Inflammation Plate MCE,SP20299LPS,H21,Indirubin-3'-monoxime,Indirubin-3'-monoxime,2,m,b139456,160807-49-8,277.28,GSK-3;GSK-3;5-Lipoxygenase,Free Base,O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=N/O,21,8,"Indirubin-3'-monoxime is a potent <b>GSK-3_</b> inhibitor; and a less potent inhibitor of <b>5-Lipoxygenase</b>; with <b>IC<sub>50</sub></b>s of 22 nM and 7.8-10 µM; respectively; also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B; with <b>IC<sub>50</sub></b>s of 100 and 180 nM.
HYCPK548 1:5 Dilution,Plate 4,D11,Inflammation Plate MCE,SP20299LPS,H22,PD 169316,PD 169316,2,m,b133377,152121-53-4,360.34,p38 MAPK;Autophagy,Free Base,FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=C([N+]([O-])=O)C=C4)=N2,22,8,"PD 169316 is a potent; cell-permeable and selective <b>p38 MAP kinase</b> inhibitor; with <b>IC<sub>50</sub></b> of 89 nM.
HYCPK547,Plate 1,E01,Inflammation Plate MCE,SP20299LPS,I01,DMSO_I01,DMSO_I01,-1,m,,,,,,,1,9
HYCPK548,Plate 2,E01,Inflammation Plate MCE,SP20299LPS,I02,DMSO_I02,DMSO_I02,-1,m,,,,,,,2,9
HYCPK547,Plate 1,E02,Inflammation Plate MCE,SP20299LPS,I03,SRT3190,SRT3190,10,m,b138422,1204707-73-2,475.53,CXCR;CXCR,Free Base,OC[C@@H]([C@@H](NC1=CC(NS(N2CCC2)(=O)=O)=NC(SCC3=C(C(F)=CC=C3)F)=N1)C)O,3,9,SRT3190 is CXCR2 ligand.
HYCPK548,Plate 2,E02,Inflammation Plate MCE,SP20299LPS,I04,BMS-345541 (free base),BMS-345541 (free base),10,m,b144341,445430-58-0,255.32,IKK,Free Base,CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21,4,9,"BMS-345541 free base is a highly selective inhibitor of the catalytic subunits of <b>IKK-2</b> and <b>IKK-1</b> with <b>IC<sub>50</sub></b> of 0.3 _M and 4 _M; respectively.
HYCPK547,Plate 1,E03,Inflammation Plate MCE,SP20299LPS,I05,Parecoxib,Parecoxib,10,m,b156964,198470-84-7,370.42,COX,Free Base,CCC(NS(=O)(C1=CC=C(C2=C(C)ON=C2C3=CC=CC=C3)C=C1)=O)=O,5,9,"Parecoxib is a potent and selective COX-2 inhibitor.
HYCPK548,Plate 2,E03,Inflammation Plate MCE,SP20299LPS,I06,Benzydamine (hydrochloride),Benzydamine (hydrochloride),10,m,b136262,132-69-4,345.87,PGE synthase,Hydrochloride,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3.[H]Cl,6,9,Benzydamine Hcl is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties; selectively binds to prostaglandin synthetase and has notable in vitro antibacterial activity.
HYCPK547,Plate 1,E04,Inflammation Plate MCE,SP20299LPS,I07,Y-320,Y-320,10,m,b143000,288250-47-5,505.01,Interleukin Related,Free Base,O=C(C1=C(C)N(C2=CC=C(Cl)C=C2)N=C1)NC3=CC=C(N4CCC(N5CCOCC5)CC4)C(C#N)=C3,7,9,"Y-320 is a new phenylpyrazoleanilide immunomodulator; inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.
HYCPK548,Plate 2,E04,Inflammation Plate MCE,SP20299LPS,I08,Eltrombopag,Eltrombopag,10,m,b134203,496775-61-2,442.47,Thrombopoietin Receptor,Free Acid,O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O,8,9,"Eltrombopag(SB-497115) is a new; orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.
HYCPK547,Plate 1,E05,Inflammation Plate MCE,SP20299LPS,I09,MK591,MK591,10,m,b145990,147030-01-1,609.15,FLAP,Sodium,[O-]C(C(C)(C)CC(N1CC2=CC=C(Cl)C=C2)=C(SC(C)(C)C)C3=C1C=CC(OCC4=NC5=CC=CC=C5C=C4)=C3)=O.[Na+],9,9,"MK591 is a selective and specific 5-Lipoxygenase-activating protein (<b>FLAP</b>) inhibitor.
HYCPK548,Plate 2,E05,Inflammation Plate MCE,SP20299LPS,I10,AS1517499,AS1517499,10,m,b139759,919486-40-1,397.86,STAT;STAT,Free Base,O=C(C1=CN=C(NCCC2=CC=C(O)C(Cl)=C2)N=C1NCC3=CC=CC=C3)N,10,9,"AS1517499 is a potent <b>STAT6</b> inhibitor with <b>IC<sub>50</sub></b> of 21 nM.
HYCPK547,Plate 1,E06,Inflammation Plate MCE,SP20299LPS,I11,Mianserin (hydrochloride),Mianserin (hydrochloride),10,m,b144757,21535-47-7,300.83,Histamine Receptor;Histamine Receptor,Hydrochloride,CN(CC1)CC2N1C3=CC=CC=C3CC4=CC=CC=C24.Cl,11,9,"Mianserin hydrochloride is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant.
HYCPK548,Plate 2,E06,Inflammation Plate MCE,SP20299LPS,I12,VGX-1027,VGX-1027,10,m,b136094,6501-72-0,205.21,Interleukin Related,Free Acid,O=C(O)CC1CC(C2=CC=CC=C2)=NO1,12,9,"VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta; TNF-alpha and IL-10 from purified murine macrophages.
HYCPK547,Plate 1,E07,Inflammation Plate MCE,SP20299LPS,I13,Cimetidine,Cimetidine,10,m,b144182,51481-61-9,252.34,Histamine Receptor;Histamine Receptor,Free Base,CC1=C(CSCC/N=C(NC)/NC#N)NC=N1,13,9,"Cimetidine is a histamine-2 (H2) receptor antagonist.
HYCPK548,Plate 2,E07,Inflammation Plate MCE,SP20299LPS,I14,VX-702,VX-702,10,m,b134828,745833-23-2,404.32,p38 MAPK,Free Base,O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O,14,9,"VX-702 is a highly selective inhibitor of p38_ MAPK(IC50=4 -20 nM); 14-fold higher potency against the p38_ versus p38_.
HYCPK547,Plate 1,E08,Inflammation Plate MCE,SP20299LPS,I15,MCC950 (sodium),MCC950 (sodium),10,m,b140355,256373-96-3,426.46,NOD-like Receptor (NLR),Sodium,O=S(C1=CC(C(C)(O)C)=CO1)([N-]C(NC2=C3CCCC3=CC4=C2CCC4)=O)=O.[Na+],15,9,"MCC950 sodium is a potent; selective <b>NLRP3</b> inhibitor with <b>IC<sub>50</sub></b> of 7.5 nM and 8.1 nM in BMDMs and HMDMs; respectively.
HYCPK548,Plate 2,E08,Inflammation Plate MCE,SP20299LPS,I16,Peficitinib,Peficitinib,10,m,b137776,944118-01-8,326.39,JAK;JAK;JAK,Free Base,O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O,16,9,"Peficitinib is an oral <b>JAK</b> inhibitor; with <b>IC<sub>50</sub></b>s of 3.9; 5.0; 0.7 and 4.8 nM for JAK1; JAK2; JAK3 and Tyk2; respectively.
HYCPK547,Plate 1,E09,Inflammation Plate MCE,SP20299LPS,I17,Histamine (phosphate),Histamine (phosphate),10,m,b145299,51-74-1,307.14,Histamine Receptor;Histamine Receptor,Phosphate,NCCC1=CNC=N1.O=P(O)(O)O.O=P(O)(O)O,17,9,Histamine diphosphate is a potent agonist of histamine receptors and vasodilator. It can activate nitric oxide synthetase.
HYCPK548,Plate 2,E09,Inflammation Plate MCE,SP20299LPS,I18,HPGDS inhibitor 1,HPGDS inhibitor 1,10,m,b137783,1033836-12-2,381.37,PGE synthase,Free Base,O=C(NC1CCN(CC(F)(F)F)CC1)C2=CC=C(C3=CC=CC(F)=C3)N=C2,18,9,"HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.
HYCPK547,Plate 1,E10,Inflammation Plate MCE,SP20299LPS,I19,Plerixafor,Plerixafor,10,m,b137689,110078-46-1,502.78,CXCR;CXCR,Free Base,C1(CN2CCCNCCNCCCNCC2)=CC=C(C=C1)CN3CCNCCCNCCNCCC3,19,9,"Plerixafor is a selective <b>CXCR4</b> antagonist with <b>IC<sub>50</sub></b> of 44 nM.
HYCPK548,Plate 2,E10,Inflammation Plate MCE,SP20299LPS,I20,TAK-659 (hydrochloride),TAK-659 (hydrochloride),10,m,b133426,1952251-28-3,380.85,Syk,Hydrochloride,FC1=C(N[C@@H]2CCCC[C@@H]2N)N=C(C3=CN(C)N=C3)C4=C1CNC4=O.Cl,20,9,"TAK-659 hydrochloride is a potent; selective and orally available spleen tyrosine kinase (<b>Syk</b>) inhibitor with an <b>IC<sub>50</sub></b> of 3.2 nM.
HYCPK547,Plate 1,E11,Inflammation Plate MCE,SP20299LPS,I21,BYL-719,BYL-719,10,m,b136862,1217486-61-7,441.47,PI3K,,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3,21,9,"BYL-719 is a potent and selective <b>PI3K_</b> inhibitor with <b>IC<sub>50</sub></b> of 5 nM.
HYCPK548,Plate 2,E11,Inflammation Plate MCE,SP20299LPS,I22,Artesunate,Artesunate,10,m,b136412,88495-63-0,384.42,STAT;STAT,Free Acid,O=C(O[C@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1)CCC(O)=O,22,9,"Artesunate is an inhibitor of both <b>STAT-3</b> and <b>exported protein 1</b> (<b>EXP1</b>). 
HYCPK547 1:5 Dilution,Plate 3,E01,Inflammation Plate MCE,SP20299LPS,J01,DMSO_J01,DMSO_J01,-1,m,,,,,,,1,10
HYCPK548 1:5 Dilution,Plate 4,E01,Inflammation Plate MCE,SP20299LPS,J02,DMSO_J02,DMSO_J02,-1,m,,,,,,,2,10
HYCPK547 1:5 Dilution,Plate 3,E02,Inflammation Plate MCE,SP20299LPS,J03,SRT3190,SRT3190,2,m,b138422,1204707-73-2,475.53,CXCR;CXCR,Free Base,OC[C@@H]([C@@H](NC1=CC(NS(N2CCC2)(=O)=O)=NC(SCC3=C(C(F)=CC=C3)F)=N1)C)O,3,10,SRT3190 is CXCR2 ligand.
HYCPK548 1:5 Dilution,Plate 4,E02,Inflammation Plate MCE,SP20299LPS,J04,BMS-345541 (free base),BMS-345541 (free base),2,m,b144341,445430-58-0,255.32,IKK,Free Base,CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21,4,10,"BMS-345541 free base is a highly selective inhibitor of the catalytic subunits of <b>IKK-2</b> and <b>IKK-1</b> with <b>IC<sub>50</sub></b> of 0.3 _M and 4 _M; respectively.
HYCPK547 1:5 Dilution,Plate 3,E03,Inflammation Plate MCE,SP20299LPS,J05,Parecoxib,Parecoxib,2,m,b156964,198470-84-7,370.42,COX,Free Base,CCC(NS(=O)(C1=CC=C(C2=C(C)ON=C2C3=CC=CC=C3)C=C1)=O)=O,5,10,"Parecoxib is a potent and selective COX-2 inhibitor.
HYCPK548 1:5 Dilution,Plate 4,E03,Inflammation Plate MCE,SP20299LPS,J06,Benzydamine (hydrochloride),Benzydamine (hydrochloride),2,m,b136262,132-69-4,345.87,PGE synthase,Hydrochloride,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3.[H]Cl,6,10,Benzydamine Hcl is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties; selectively binds to prostaglandin synthetase and has notable in vitro antibacterial activity.
HYCPK547 1:5 Dilution,Plate 3,E04,Inflammation Plate MCE,SP20299LPS,J07,Y-320,Y-320,2,m,b143000,288250-47-5,505.01,Interleukin Related,Free Base,O=C(C1=C(C)N(C2=CC=C(Cl)C=C2)N=C1)NC3=CC=C(N4CCC(N5CCOCC5)CC4)C(C#N)=C3,7,10,"Y-320 is a new phenylpyrazoleanilide immunomodulator; inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.
HYCPK548 1:5 Dilution,Plate 4,E04,Inflammation Plate MCE,SP20299LPS,J08,Eltrombopag,Eltrombopag,2,m,b134203,496775-61-2,442.47,Thrombopoietin Receptor,Free Acid,O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O,8,10,"Eltrombopag(SB-497115) is a new; orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.
HYCPK547 1:5 Dilution,Plate 3,E05,Inflammation Plate MCE,SP20299LPS,J09,MK591,MK591,2,m,b145990,147030-01-1,609.15,FLAP,Sodium,[O-]C(C(C)(C)CC(N1CC2=CC=C(Cl)C=C2)=C(SC(C)(C)C)C3=C1C=CC(OCC4=NC5=CC=CC=C5C=C4)=C3)=O.[Na+],9,10,"MK591 is a selective and specific 5-Lipoxygenase-activating protein (<b>FLAP</b>) inhibitor.
HYCPK548 1:5 Dilution,Plate 4,E05,Inflammation Plate MCE,SP20299LPS,J10,AS1517499,AS1517499,2,m,b139759,919486-40-1,397.86,STAT;STAT,Free Base,O=C(C1=CN=C(NCCC2=CC=C(O)C(Cl)=C2)N=C1NCC3=CC=CC=C3)N,10,10,"AS1517499 is a potent <b>STAT6</b> inhibitor with <b>IC<sub>50</sub></b> of 21 nM.
HYCPK547 1:5 Dilution,Plate 3,E06,Inflammation Plate MCE,SP20299LPS,J11,Mianserin (hydrochloride),Mianserin (hydrochloride),2,m,b144757,21535-47-7,300.83,Histamine Receptor;Histamine Receptor,Hydrochloride,CN(CC1)CC2N1C3=CC=CC=C3CC4=CC=CC=C24.Cl,11,10,"Mianserin hydrochloride is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant.
HYCPK548 1:5 Dilution,Plate 4,E06,Inflammation Plate MCE,SP20299LPS,J12,VGX-1027,VGX-1027,2,m,b136094,6501-72-0,205.21,Interleukin Related,Free Acid,O=C(O)CC1CC(C2=CC=CC=C2)=NO1,12,10,"VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta; TNF-alpha and IL-10 from purified murine macrophages.
HYCPK547 1:5 Dilution,Plate 3,E07,Inflammation Plate MCE,SP20299LPS,J13,Cimetidine,Cimetidine,2,m,b144182,51481-61-9,252.34,Histamine Receptor;Histamine Receptor,Free Base,CC1=C(CSCC/N=C(NC)/NC#N)NC=N1,13,10,"Cimetidine is a histamine-2 (H2) receptor antagonist.
HYCPK548 1:5 Dilution,Plate 4,E07,Inflammation Plate MCE,SP20299LPS,J14,VX-702,VX-702,2,m,b134828,745833-23-2,404.32,p38 MAPK,Free Base,O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O,14,10,"VX-702 is a highly selective inhibitor of p38_ MAPK(IC50=4 -20 nM); 14-fold higher potency against the p38_ versus p38_.
HYCPK547 1:5 Dilution,Plate 3,E08,Inflammation Plate MCE,SP20299LPS,J15,MCC950 (sodium),MCC950 (sodium),2,m,b140355,256373-96-3,426.46,NOD-like Receptor (NLR),Sodium,O=S(C1=CC(C(C)(O)C)=CO1)([N-]C(NC2=C3CCCC3=CC4=C2CCC4)=O)=O.[Na+],15,10,"MCC950 sodium is a potent; selective <b>NLRP3</b> inhibitor with <b>IC<sub>50</sub></b> of 7.5 nM and 8.1 nM in BMDMs and HMDMs; respectively.
HYCPK548 1:5 Dilution,Plate 4,E08,Inflammation Plate MCE,SP20299LPS,J16,Peficitinib,Peficitinib,2,m,b137776,944118-01-8,326.39,JAK;JAK;JAK,Free Base,O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O,16,10,"Peficitinib is an oral <b>JAK</b> inhibitor; with <b>IC<sub>50</sub></b>s of 3.9; 5.0; 0.7 and 4.8 nM for JAK1; JAK2; JAK3 and Tyk2; respectively.
HYCPK547 1:5 Dilution,Plate 3,E09,Inflammation Plate MCE,SP20299LPS,J17,Histamine (phosphate),Histamine (phosphate),2,m,b145299,51-74-1,307.14,Histamine Receptor;Histamine Receptor,Phosphate,NCCC1=CNC=N1.O=P(O)(O)O.O=P(O)(O)O,17,10,Histamine diphosphate is a potent agonist of histamine receptors and vasodilator. It can activate nitric oxide synthetase.
HYCPK548 1:5 Dilution,Plate 4,E09,Inflammation Plate MCE,SP20299LPS,J18,HPGDS inhibitor 1,HPGDS inhibitor 1,2,m,b137783,1033836-12-2,381.37,PGE synthase,Free Base,O=C(NC1CCN(CC(F)(F)F)CC1)C2=CC=C(C3=CC=CC(F)=C3)N=C2,18,10,"HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.
HYCPK547 1:5 Dilution,Plate 3,E10,Inflammation Plate MCE,SP20299LPS,J19,Plerixafor,Plerixafor,2,m,b137689,110078-46-1,502.78,CXCR;CXCR,Free Base,C1(CN2CCCNCCNCCCNCC2)=CC=C(C=C1)CN3CCNCCCNCCNCCC3,19,10,"Plerixafor is a selective <b>CXCR4</b> antagonist with <b>IC<sub>50</sub></b> of 44 nM.
HYCPK548 1:5 Dilution,Plate 4,E10,Inflammation Plate MCE,SP20299LPS,J20,TAK-659 (hydrochloride),TAK-659 (hydrochloride),2,m,b133426,1952251-28-3,380.85,Syk,Hydrochloride,FC1=C(N[C@@H]2CCCC[C@@H]2N)N=C(C3=CN(C)N=C3)C4=C1CNC4=O.Cl,20,10,"TAK-659 hydrochloride is a potent; selective and orally available spleen tyrosine kinase (<b>Syk</b>) inhibitor with an <b>IC<sub>50</sub></b> of 3.2 nM.
HYCPK547 1:5 Dilution,Plate 3,E11,Inflammation Plate MCE,SP20299LPS,J21,BYL-719,BYL-719,2,m,b136862,1217486-61-7,441.47,PI3K,,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3,21,10,"BYL-719 is a potent and selective <b>PI3K_</b> inhibitor with <b>IC<sub>50</sub></b> of 5 nM.
HYCPK548 1:5 Dilution,Plate 4,E11,Inflammation Plate MCE,SP20299LPS,J22,Artesunate,Artesunate,2,m,b136412,88495-63-0,384.42,STAT;STAT,Free Acid,O=C(O[C@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1)CCC(O)=O,22,10,"Artesunate is an inhibitor of both <b>STAT-3</b> and <b>exported protein 1</b> (<b>EXP1</b>). 
HYCPK547,Plate 1,F01,Inflammation Plate MCE,SP20299LPS,K01,DMSO_K01,DMSO_K01,-1,m,,,,,,,1,11
HYCPK548,Plate 2,F01,Inflammation Plate MCE,SP20299LPS,K02,DMSO_K02,DMSO_K02,-1,m,,,,,,,2,11
HYCPK547,Plate 1,F02,Inflammation Plate MCE,SP20299LPS,K03,L-Canavanine sulfate,L-Canavanine sulfate,10,m,b135973,2219-31-0,274.25,NO Synthase,Sulfate,N[C@@H](CCONC(N)=N)C(O)=O.O=S(O)(O)=O,3,11,"L-Canavanine sulfate is a selective inhibitor of inducible <b>NO synthase</b>.
HYCPK548,Plate 2,F02,Inflammation Plate MCE,SP20299LPS,K04,BEZ235 (Tosylate),BEZ235 (Tosylate),10,m,b136030,1028385-32-1,641.74,PI3K;mTOR;Autophagy,Tosylate,CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7,4,11,"BEZ235 Tosylate is a dual <b>PI3K</b> and <b>mTOR</b> kinase inhibitor with <b>IC<sub>50</sub></b> values of 4; 75; 7; 5 nM for PI3K_; _; _; _; respectively.
HYCPK547,Plate 1,F03,Inflammation Plate MCE,SP20299LPS,K05,UNBS5162,UNBS5162,10,m,b134907,956590-23-1,326.35,CXCR;CXCR;Autophagy,Free Base,O=C(N)NC1=CC2=CC=CC(C(N(CCN(C)C)C3=O)=O)=C2C3=C1,5,11,"UNBS5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers; the mean antiproliferative activity IC50 value is 17.9 uM for 9 cancer cell lines; hydrolysis product of UNBS3157.
HYCPK548,Plate 2,F03,Inflammation Plate MCE,SP20299LPS,K06,Baricitinib,Baricitinib,10,m,b134374,1187594-09-7,371.42,JAK;JAK;JAK,Free Base,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1,6,11,"Baricitinib is a selective orally bioavailable <b>JAK1</b>/<b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of 5.9 nM and 5.7 nM; respectively.
HYCPK547,Plate 1,F04,Inflammation Plate MCE,SP20299LPS,K07,Hydroxychloroquine sulfate,Hydroxychloroquine sulfate,10,m,b135408,747-36-4,433.95,Toll-like Receptor (TLR);Parasite ,Sulfate,CCN(CCO)CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C.O=S(O)(O)=O,7,11,"Hydroxychloroquine sulfate is a synthetic <b>antimalarial</b> drug which can also inhibit <b>Toll-like receptor 7/9</b> (<b>TLR7/9</b>) signaling.
HYCPK548,Plate 2,F04,Inflammation Plate MCE,SP20299LPS,K08,APY0201,APY0201,10,m,b134162,1232221-74-7,413.48,Interleukin Related;PIKfyve,Free Base,CC1=CC(/C=N/NC2=NC3=CC(C4=CC=NC=C4)=NN3C(N5CCOCC5)=C2)=CC=C1,8,11,"APY0201 is a potent <b>PIKfyve</b> inhibitor; which inhibits the conversion of PtdIns3P to PtdIns(3;5)P<sub>2</sub> in the presence of in the presence of [<sup>33</sup>P]ATP with an <b>IC<sub>50</sub></b> of 5.2 nM. APY0201 also inhibits <b>IL-12/IL-23</b> production.
HYCPK547,Plate 1,F05,Inflammation Plate MCE,SP20299LPS,K09,Agmatine (sulfate),Agmatine (sulfate),10,m,b139035,2482-00-0,228.27,Imidazoline Receptor;Imidazoline Receptor;NO Synthase,Sulfate,NC(NCCCCN)=N.O=S(O)(O)=O,9,11,"Agmatine sulfate exerts modulatory action at multiple molecular targets; such as neurotransmitter systems; ion channels and nitric oxide synthesis. It is an endogenous agonist at <b>imidazoline receptor</b> and a <b>NO synthase</b> inhibitor. 
HYCPK548,Plate 2,F05,Inflammation Plate MCE,SP20299LPS,K10,Zomepirac (sodium salt),Zomepirac (sodium salt),10,m,b137562,64092-48-4,313.71,PGE synthase,Sodium,[O-]C(CC1=CC(C)=C(C(C2=CC=C(Cl)C=C2)=O)N1C)=O.[Na+],10,11,Zomepirac sodium salt is a pyrrole-acetic acid structurally related to tolmetin sodium; a prostaglandin synthetase inhibitor.
HYCPK547,Plate 1,F06,Inflammation Plate MCE,SP20299LPS,K11,GIBH-130,GIBH-130,10,m,b144186,1252608-59-5,360.41,Interleukin Related,Free Base,O=C(C1=NN=C(C2=CC=CC=C2)C=C1C)N3CCN(C4=NC=CC=N4)CC3,11,11,"GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the <b>IL-1_</b> secretion by activated microglia (<b>IC<sub>50</sub></b>=3.4 nM).
HYCPK548,Plate 2,F06,Inflammation Plate MCE,SP20299LPS,K12,Nizatidine,Nizatidine,10,m,b144124,76963-41-2,331.46,Histamine Receptor;Histamine Receptor,Free Base,CN/C(NCCSCC1=CSC(CN(C)C)=N1)=C\[N+]([O-])=O,12,11,"Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.
HYCPK547,Plate 1,F07,Inflammation Plate MCE,SP20299LPS,K13,JSH-23,JSH-23,10,m,b144927,749886-87-1,240.34,NF-_B,Free Base,NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2,13,11,"JSH-23 is an inhibitor of <b>NF-_B</b> with an <b>IC<sub>50</sub></b> value of 7.1 _M.
HYCPK548,Plate 2,F07,Inflammation Plate MCE,SP20299LPS,K14,WP1066,WP1066,10,m,b134391,857064-38-1,356.22,JAK;JAK;JAK;STAT;STAT,Free Base,O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2,14,11,"WP1066 is a novel inhibitor of <b>JAK2</b> and <b>STAT3</b>; and also shows effect on STAT5 and ERK1/2; without affecting JAK1 and JAK3.
HYCPK547,Plate 1,F08,Inflammation Plate MCE,SP20299LPS,K15,GLPG0634,GLPG0634,10,m,b145725,1206161-97-8,425.5,JAK;JAK;JAK,Free Base,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2,15,11,"GLPG0634 is a selective <b>JAK1</b> inhibitor with <b>IC<sub>50</sub></b> of 10 nM; 28 nM; 810 nM; and 116 nM for JAK1; JAK2; JAK3; and TYK2; respectively.
HYCPK548,Plate 2,F08,Inflammation Plate MCE,SP20299LPS,K16,NVP-BKM120 (Hydrochloride),NVP-BKM120 (Hydrochloride),10,m,b144305,1312445-63-8,446.85,PI3K,Hydrochloride,NC(N=C1)=CC(C(F)(F)F)=C1C2=NC(N3CCOCC3)=NC(N4CCOCC4)=C2.[H]Cl,16,11,"NVP-BKM120 Hydrochloride is a pan-class I <b>PI3K</b> inhibitor; with <b>IC<sub>50</sub></b> of 52 nM/166 nM/116 nM/262 nM for <b>p110_</b>/<b>p110_</b>/<b>p110_</b>/<b>p110_</b>; respectively.
HYCPK547,Plate 1,F09,Inflammation Plate MCE,SP20299LPS,K17,KU-0063794,KU-0063794,10,m,b138411,938440-64-3,465.54,mTOR,Free Base,OCC1=CC(C2=CC=C3C(N=C(N=C3N4CCOCC4)N5C[C@@H](O[C@@H](C5)C)C)=N2)=CC=C1OC,17,11,"KU-0063794 is a potent and highly specific dual-<b>mTOR</b> inhibitor; with <b>IC<sub>50</sub></b> of appr 10 nM for <b>mTORC1</b> and <b>mTORC2</b> in cell-free assays; but has no effect on PI3Ks.
HYCPK548,Plate 2,F09,Inflammation Plate MCE,SP20299LPS,K18,L-NIL,L-NIL,10,m,b144459,53774-63-3,187.24,NO Synthase,Free Base,N[C@@H](CCCCNC(C)=N)C(O)=O,18,11,"L-NIL is a potent and selective inhibitor of inducible <b>NO synthase</b> with <b>IC<sub>50</sub></b>s of 3.3 and 92 _M for mouse inducible NO synthase and rat brain constitutive NO synthase; respectively. 
HYCPK547,Plate 1,F10,Inflammation Plate MCE,SP20299LPS,K19,Tomatidine,Tomatidine,10,m,b135162,77-59-8,415.65,JNK;NF-_B,Free Base,[H][C@]1(O[C@]2(NC[C@@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC[C@@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H],19,11,"Tomatidine acts as an anti-inflammatory agent by blocking <b>NF-_B</b> and <b>JNK</b> signaling.
HYCPK548,Plate 2,F10,Inflammation Plate MCE,SP20299LPS,K20,IRAK-1-4 Inhibitor I,IRAK-1-4 Inhibitor I,10,m,b138773,509093-47-4,395.41,IRAK;IRAK,Free Base,O=C(C1=CC=CC([N+]([O-])=O)=C1)NC2=NC3=CC=CC=C3N2CCN4CCOCC4,20,11,"IRAK-1-4 Inhibitor I is a dual inhibitor of <b>IRAK4</b> and <b>IRAK1</b> with <b>IC<sub>50</sub></b> of 0.2 _M and 0.3 _M; respectively.
HYCPK547,Plate 1,F11,Inflammation Plate MCE,SP20299LPS,K21,Napabucasin,Napabucasin,10,m,b138263,83280-65-3,240.21,STAT;STAT,Free Base,O=C(C1=C2OC(C(C)=O)=C1)C3=C(C2=O)C=CC=C3,21,11,"Napabucasin is a newly found small molecule with the ability to inhibit gene transcription of <b>STAT3</b>; which is able to suppress cancer stemness properties and induce cell death.
HYCPK548,Plate 2,F11,Inflammation Plate MCE,SP20299LPS,K22,ZSTK474,ZSTK474,10,m,b138392,475110-96-4,417.41,PI3K;Autophagy,Free Base,FC(C1=NC2=C(N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3)C=CC=C2)F,22,11,"ZSTK474 is an ATP-competitive pan-class I <b>PI3K</b> inhibitor with <b>IC<sub>50</sub></b>s of16 nM; 44 nM; 4.6 nM and 49 nM for P_3__; PI3K_; PI3K_ and PI3K_; respectively.
HYCPK547 1:5 Dilution,Plate 3,F01,Inflammation Plate MCE,SP20299LPS,L01,DMSO_L01,DMSO_L01,-1,m,,,,,,,1,12
HYCPK548 1:5 Dilution,Plate 4,F01,Inflammation Plate MCE,SP20299LPS,L02,DMSO_L02,DMSO_L02,-1,m,,,,,,,2,12
HYCPK547 1:5 Dilution,Plate 3,F02,Inflammation Plate MCE,SP20299LPS,L03,L-Canavanine sulfate,L-Canavanine sulfate,2,m,b135973,2219-31-0,274.25,NO Synthase,Sulfate,N[C@@H](CCONC(N)=N)C(O)=O.O=S(O)(O)=O,3,12,"L-Canavanine sulfate is a selective inhibitor of inducible <b>NO synthase</b>.
HYCPK548 1:5 Dilution,Plate 4,F02,Inflammation Plate MCE,SP20299LPS,L04,BEZ235 (Tosylate),BEZ235 (Tosylate),2,m,b136030,1028385-32-1,641.74,PI3K;mTOR;Autophagy,Tosylate,CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7,4,12,"BEZ235 Tosylate is a dual <b>PI3K</b> and <b>mTOR</b> kinase inhibitor with <b>IC<sub>50</sub></b> values of 4; 75; 7; 5 nM for PI3K_; _; _; _; respectively.
HYCPK547 1:5 Dilution,Plate 3,F03,Inflammation Plate MCE,SP20299LPS,L05,UNBS5162,UNBS5162,2,m,b134907,956590-23-1,326.35,CXCR;CXCR;Autophagy,Free Base,O=C(N)NC1=CC2=CC=CC(C(N(CCN(C)C)C3=O)=O)=C2C3=C1,5,12,"UNBS5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers; the mean antiproliferative activity IC50 value is 17.9 uM for 9 cancer cell lines; hydrolysis product of UNBS3157.
HYCPK548 1:5 Dilution,Plate 4,F03,Inflammation Plate MCE,SP20299LPS,L06,Baricitinib,Baricitinib,2,m,b134374,1187594-09-7,371.42,JAK;JAK;JAK,Free Base,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1,6,12,"Baricitinib is a selective orally bioavailable <b>JAK1</b>/<b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of 5.9 nM and 5.7 nM; respectively.
HYCPK547 1:5 Dilution,Plate 3,F04,Inflammation Plate MCE,SP20299LPS,L07,Hydroxychloroquine sulfate,Hydroxychloroquine sulfate,2,m,b135408,747-36-4,433.95,Toll-like Receptor (TLR);Parasite ,Sulfate,CCN(CCO)CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C.O=S(O)(O)=O,7,12,"Hydroxychloroquine sulfate is a synthetic <b>antimalarial</b> drug which can also inhibit <b>Toll-like receptor 7/9</b> (<b>TLR7/9</b>) signaling.
HYCPK548 1:5 Dilution,Plate 4,F04,Inflammation Plate MCE,SP20299LPS,L08,APY0201,APY0201,2,m,b134162,1232221-74-7,413.48,Interleukin Related;PIKfyve,Free Base,CC1=CC(/C=N/NC2=NC3=CC(C4=CC=NC=C4)=NN3C(N5CCOCC5)=C2)=CC=C1,8,12,"APY0201 is a potent <b>PIKfyve</b> inhibitor; which inhibits the conversion of PtdIns3P to PtdIns(3;5)P<sub>2</sub> in the presence of in the presence of [<sup>33</sup>P]ATP with an <b>IC<sub>50</sub></b> of 5.2 nM. APY0201 also inhibits <b>IL-12/IL-23</b> production.
HYCPK547 1:5 Dilution,Plate 3,F05,Inflammation Plate MCE,SP20299LPS,L09,Agmatine (sulfate),Agmatine (sulfate),2,m,b139035,2482-00-0,228.27,Imidazoline Receptor;Imidazoline Receptor;NO Synthase,Sulfate,NC(NCCCCN)=N.O=S(O)(O)=O,9,12,"Agmatine sulfate exerts modulatory action at multiple molecular targets; such as neurotransmitter systems; ion channels and nitric oxide synthesis. It is an endogenous agonist at <b>imidazoline receptor</b> and a <b>NO synthase</b> inhibitor. 
HYCPK548 1:5 Dilution,Plate 4,F05,Inflammation Plate MCE,SP20299LPS,L10,Zomepirac (sodium salt),Zomepirac (sodium salt),2,m,b137562,64092-48-4,313.71,PGE synthase,Sodium,[O-]C(CC1=CC(C)=C(C(C2=CC=C(Cl)C=C2)=O)N1C)=O.[Na+],10,12,Zomepirac sodium salt is a pyrrole-acetic acid structurally related to tolmetin sodium; a prostaglandin synthetase inhibitor.
HYCPK547 1:5 Dilution,Plate 3,F06,Inflammation Plate MCE,SP20299LPS,L11,GIBH-130,GIBH-130,2,m,b144186,1252608-59-5,360.41,Interleukin Related,Free Base,O=C(C1=NN=C(C2=CC=CC=C2)C=C1C)N3CCN(C4=NC=CC=N4)CC3,11,12,"GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the <b>IL-1_</b> secretion by activated microglia (<b>IC<sub>50</sub></b>=3.4 nM).
HYCPK548 1:5 Dilution,Plate 4,F06,Inflammation Plate MCE,SP20299LPS,L12,Nizatidine,Nizatidine,2,m,b144124,76963-41-2,331.46,Histamine Receptor;Histamine Receptor,Free Base,CN/C(NCCSCC1=CSC(CN(C)C)=N1)=C\[N+]([O-])=O,12,12,"Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.
HYCPK547 1:5 Dilution,Plate 3,F07,Inflammation Plate MCE,SP20299LPS,L13,JSH-23,JSH-23,2,m,b144927,749886-87-1,240.34,NF-_B,Free Base,NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2,13,12,"JSH-23 is an inhibitor of <b>NF-_B</b> with an <b>IC<sub>50</sub></b> value of 7.1 _M.
HYCPK548 1:5 Dilution,Plate 4,F07,Inflammation Plate MCE,SP20299LPS,L14,WP1066,WP1066,2,m,b134391,857064-38-1,356.22,JAK;JAK;JAK;STAT;STAT,Free Base,O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2,14,12,"WP1066 is a novel inhibitor of <b>JAK2</b> and <b>STAT3</b>; and also shows effect on STAT5 and ERK1/2; without affecting JAK1 and JAK3.
HYCPK547 1:5 Dilution,Plate 3,F08,Inflammation Plate MCE,SP20299LPS,L15,GLPG0634,GLPG0634,2,m,b145725,1206161-97-8,425.5,JAK;JAK;JAK,Free Base,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2,15,12,"GLPG0634 is a selective <b>JAK1</b> inhibitor with <b>IC<sub>50</sub></b> of 10 nM; 28 nM; 810 nM; and 116 nM for JAK1; JAK2; JAK3; and TYK2; respectively.
HYCPK548 1:5 Dilution,Plate 4,F08,Inflammation Plate MCE,SP20299LPS,L16,NVP-BKM120 (Hydrochloride),NVP-BKM120 (Hydrochloride),2,m,b144305,1312445-63-8,446.85,PI3K,Hydrochloride,NC(N=C1)=CC(C(F)(F)F)=C1C2=NC(N3CCOCC3)=NC(N4CCOCC4)=C2.[H]Cl,16,12,"NVP-BKM120 Hydrochloride is a pan-class I <b>PI3K</b> inhibitor; with <b>IC<sub>50</sub></b> of 52 nM/166 nM/116 nM/262 nM for <b>p110_</b>/<b>p110_</b>/<b>p110_</b>/<b>p110_</b>; respectively.
HYCPK547 1:5 Dilution,Plate 3,F09,Inflammation Plate MCE,SP20299LPS,L17,KU-0063794,KU-0063794,2,m,b138411,938440-64-3,465.54,mTOR,Free Base,OCC1=CC(C2=CC=C3C(N=C(N=C3N4CCOCC4)N5C[C@@H](O[C@@H](C5)C)C)=N2)=CC=C1OC,17,12,"KU-0063794 is a potent and highly specific dual-<b>mTOR</b> inhibitor; with <b>IC<sub>50</sub></b> of appr 10 nM for <b>mTORC1</b> and <b>mTORC2</b> in cell-free assays; but has no effect on PI3Ks.
HYCPK548 1:5 Dilution,Plate 4,F09,Inflammation Plate MCE,SP20299LPS,L18,L-NIL,L-NIL,2,m,b144459,53774-63-3,187.24,NO Synthase,Free Base,N[C@@H](CCCCNC(C)=N)C(O)=O,18,12,"L-NIL is a potent and selective inhibitor of inducible <b>NO synthase</b> with <b>IC<sub>50</sub></b>s of 3.3 and 92 _M for mouse inducible NO synthase and rat brain constitutive NO synthase; respectively. 
HYCPK547 1:5 Dilution,Plate 3,F10,Inflammation Plate MCE,SP20299LPS,L19,Tomatidine,Tomatidine,2,m,b135162,77-59-8,415.65,JNK;NF-_B,Free Base,[H][C@]1(O[C@]2(NC[C@@H](C)CC2)[C@H]3C)C[C@@]4([H])[C@]5([H])CC[C@@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]13[H],19,12,"Tomatidine acts as an anti-inflammatory agent by blocking <b>NF-_B</b> and <b>JNK</b> signaling.
HYCPK548 1:5 Dilution,Plate 4,F10,Inflammation Plate MCE,SP20299LPS,L20,IRAK-1-4 Inhibitor I,IRAK-1-4 Inhibitor I,2,m,b138773,509093-47-4,395.41,IRAK;IRAK,Free Base,O=C(C1=CC=CC([N+]([O-])=O)=C1)NC2=NC3=CC=CC=C3N2CCN4CCOCC4,20,12,"IRAK-1-4 Inhibitor I is a dual inhibitor of <b>IRAK4</b> and <b>IRAK1</b> with <b>IC<sub>50</sub></b> of 0.2 _M and 0.3 _M; respectively.
HYCPK547 1:5 Dilution,Plate 3,F11,Inflammation Plate MCE,SP20299LPS,L21,Napabucasin,Napabucasin,2,m,b138263,83280-65-3,240.21,STAT;STAT,Free Base,O=C(C1=C2OC(C(C)=O)=C1)C3=C(C2=O)C=CC=C3,21,12,"Napabucasin is a newly found small molecule with the ability to inhibit gene transcription of <b>STAT3</b>; which is able to suppress cancer stemness properties and induce cell death.
HYCPK548 1:5 Dilution,Plate 4,F11,Inflammation Plate MCE,SP20299LPS,L22,ZSTK474,ZSTK474,2,m,b138392,475110-96-4,417.41,PI3K;Autophagy,Free Base,FC(C1=NC2=C(N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3)C=CC=C2)F,22,12,"ZSTK474 is an ATP-competitive pan-class I <b>PI3K</b> inhibitor with <b>IC<sub>50</sub></b>s of16 nM; 44 nM; 4.6 nM and 49 nM for P_3__; PI3K_; PI3K_ and PI3K_; respectively.
HYCPK547,Plate 1,G01,Inflammation Plate MCE,SP20299LPS,M01,DMSO_M01,DMSO_M01,-1,m,,,,,,,1,13
HYCPK548,Plate 2,G01,Inflammation Plate MCE,SP20299LPS,M02,DMSO_M02,DMSO_M02,-1,m,,,,,,,2,13
HYCPK547,Plate 1,G02,Inflammation Plate MCE,SP20299LPS,M03,PS-1145,PS-1145,10,m,b147855,431898-65-6,322.75,IKK,Free Base,O=C(C1=CC=CN=C1)NC2=CC(Cl)=CC3=C2NC4=C3C=CN=C4,3,13,"PS-1145 is an I_B kinase (<b>IKK</b>) inhibitor with an <b>IC<sub>50</sub></b> of 88 nM.
HYCPK548,Plate 2,G02,Inflammation Plate MCE,SP20299LPS,M04,Scopoletin,Scopoletin,10,m,b147104,92-61-5,192.17,AChE,Free Base,O=C1C=CC2=CC(OC)=C(O)C=C2O1,4,13,"Scopoletin is an inhibitor of acetylcholinesterase (<b>AChE</b>).
HYCPK547,Plate 1,G03,Inflammation Plate MCE,SP20299LPS,M05,Acalisib,Acalisib,10,m,b137984,870281-34-8,401.4,PI3K,Free Base,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=NC5=C1C=C(F)C=C5,5,13,"Acalisib is a potent and selective <b>PI3K_</b> inhibitor with an <b>IC<sub>50</sub></b> of 12.7 nM.
HYCPK548,Plate 2,G03,Inflammation Plate MCE,SP20299LPS,M06,TGR-1202,TGR-1202,10,m,b135721,1532533-67-7,571.55,PI3K,Free Base,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16,6,13,"TGR-1202 is a novel <b>PI3K_</b> inhibitor; with <b>IC<sub>50</sub></b> and <b>EC<sub>50</sub></b> of 22.2 nM and 24.3 nM; respectively; Also active against <b>CK1_</b>; with an <b>EC<sub>50</sub></b> value of 6.0 _M.
HYCPK547,Plate 1,G04,Inflammation Plate MCE,SP20299LPS,M07,Famotidine,Famotidine,10,m,b144214,76824-35-6,337.45,Histamine Receptor;Histamine Receptor,Free Base,N=C(NS(=O)(N)=O)CCSCC1=CSC(NC(N)=N)=N1,7,13,"Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
HYCPK548,Plate 2,G04,Inflammation Plate MCE,SP20299LPS,M08,Well_M08,Well_M08,-1,m,,,,,,,8,13
HYCPK547,Plate 1,G05,Inflammation Plate MCE,SP20299LPS,M09,WYE-125132,WYE-125132,10,m,b138269,1144068-46-1,519.6,mTOR,Free Base,O=C(NC1=CC=C(C2=NC(N3CC4CCC(C3)O4)=C5C(N(N=C5)C6CCC7(CC6)OCCO7)=N2)C=C1)NC,9,13,"WYE-125132 (WYE-132) is a highly potent; ATP-competitive; and specific <b>mTOR</b> kinase inhibitor (<b>IC<sub>50</sub></b>: 0.19±0.07 nM; >5;000-fold selective versus PI3Ks). 
HYCPK548,Plate 2,G05,Inflammation Plate MCE,SP20299LPS,M10,Well_M10,Well_M10,-1,m,,,,,,,10,13
HYCPK547,Plate 1,G06,Inflammation Plate MCE,SP20299LPS,M11,SC-514,SC-514,10,m,b148269,354812-17-2,224.3,IKK,Free Base,O=C(C1=C(N)C=C(C2=CSC=C2)S1)N,11,13,"SC-514 is a selective <b>IKK-2</b> inhibitor (<b>IC<sub>50</sub></b>=11.2±4.7 _M); which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
HYCPK548,Plate 2,G06,Inflammation Plate MCE,SP20299LPS,M12,Well_M12,Well_M12,-1,m,,,,,,,12,13
HYCPK547,Plate 1,G07,Inflammation Plate MCE,SP20299LPS,M13,Gardiquimod trifluoroacetate,Gardiquimod trifluoroacetate,10,m,b143912,1159840-61-5,541.44,Toll-like Receptor (TLR);HIV,Trifluoroacetate,OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N.FC(C(O)=O)(F)F.FC(C(O)=O)(F)F,13,13,"Gardiquimod trifluoroacetate is a specific <b>TLR7</b> agonist which can also inhibit <b>HIV-1 reverse transcriptase</b>.
HYCPK548,Plate 2,G07,Inflammation Plate MCE,SP20299LPS,M14,Well_M14,Well_M14,-1,m,,,,,,,14,13
HYCPK547,Plate 1,G08,Inflammation Plate MCE,SP20299LPS,M15,MRT67307,MRT67307,10,m,b140344,1190378-57-4,464.6,ULK;Autophagy;IKK,Free Base,O=C(NCCCNC1=NC(NC2=CC=CC(CN3CCOCC3)=C2)=NC=C1C4CC4)C5CCC5,15,13,"MRT67307 is a dual inhibitor of the <b>IKK_</b> and <b>TBK-1</b>; which mediates the phosphorylation of interferon regulatory factor 3 (IRF3); with <b>IC<sub>50</sub></b> values of 160 and 19 nM when assayed at 0.1 mM ATP in vitro; and also targets ULK1 and ULK2 with high potency (IC<sub>50</sub> values of 45 and 38 nM; respectively). 
HYCPK548,Plate 2,G08,Inflammation Plate MCE,SP20299LPS,M16,Well_M16,Well_M16,-1,m,,,,,,,16,13
HYCPK547,Plate 1,G09,Inflammation Plate MCE,SP20299LPS,M17,TAK-242,TAK-242,10,m,b143691,243984-11-4,361.82,Autophagy;Toll-like Receptor (TLR),Free Base,O=S([C@H]1C(C(OCC)=O)=CCCC1)(NC2=CC=C(C=C2Cl)F)=O,17,13,"TAK-242 is a potent <b>TLR4</b> signaling inhibitor; selectively inhibits the TLR4-mediated production of cytokines and NO.
HYCPK548,Plate 2,G09,Inflammation Plate MCE,SP20299LPS,M18,Well_M18,Well_M18,-1,m,,,,,,,18,13
HYCPK547,Plate 1,G10,Inflammation Plate MCE,SP20299LPS,M19,GS-9973,GS-9973,10,m,b136397,1229208-44-9,411.46,Syk,Free Base,C12=NC=CN1C=C(C3=CC4=C(C=C3)C=NN4)N=C2NC5=CC=C(N6CCOCC6)C=C5,19,13,"GS-9973 is an orally bioavailable; selective¾<b>Syk</b>¾inhibitor with¾<b>IC<sub>50</sub></b>¾of 7.7 nM.
HYCPK548,Plate 2,G10,Inflammation Plate MCE,SP20299LPS,M20,Well_M20,Well_M20,-1,m,,,,,,,20,13
HYCPK547,Plate 1,G11,Inflammation Plate MCE,SP20299LPS,M21,AZD-1480,AZD-1480,10,m,b145169,935666-88-9,348.77,JAK;JAK;JAK,Free Base,ClC1=C(N=C(N=C1)N[C@@H](C)C2=NC=C(C=N2)F)NC3=NNC(C)=C3,21,13,"AZD-1480 is a novel ATP-competitive <b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of < 0.4 nM; selectively against JAK3 and Tyk2; and to a smaller extent against JAK1.
HYCPK548,Plate 2,G11,Inflammation Plate MCE,SP20299LPS,M22,Well_M22,Well_M22,-1,m,,,,,,,22,13
HYCPK547 1:5 Dilution,Plate 3,G01,Inflammation Plate MCE,SP20299LPS,N01,DMSO_N01,DMSO_N01,-1,m,,,,,,,1,14
HYCPK548 1:5 Dilution,Plate 4,G01,Inflammation Plate MCE,SP20299LPS,N02,DMSO_N02,DMSO_N02,-1,m,,,,,,,2,14
HYCPK547 1:5 Dilution,Plate 3,G02,Inflammation Plate MCE,SP20299LPS,N03,PS-1145,PS-1145,2,m,b147855,431898-65-6,322.75,IKK,Free Base,O=C(C1=CC=CN=C1)NC2=CC(Cl)=CC3=C2NC4=C3C=CN=C4,3,14,"PS-1145 is an I_B kinase (<b>IKK</b>) inhibitor with an <b>IC<sub>50</sub></b> of 88 nM.
HYCPK548 1:5 Dilution,Plate 4,G02,Inflammation Plate MCE,SP20299LPS,N04,Scopoletin,Scopoletin,2,m,b147104,92-61-5,192.17,AChE,Free Base,O=C1C=CC2=CC(OC)=C(O)C=C2O1,4,14,"Scopoletin is an inhibitor of acetylcholinesterase (<b>AChE</b>).
HYCPK547 1:5 Dilution,Plate 3,G03,Inflammation Plate MCE,SP20299LPS,N05,Acalisib,Acalisib,2,m,b137984,870281-34-8,401.4,PI3K,Free Base,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=NC5=C1C=C(F)C=C5,5,14,"Acalisib is a potent and selective <b>PI3K_</b> inhibitor with an <b>IC<sub>50</sub></b> of 12.7 nM.
HYCPK548 1:5 Dilution,Plate 4,G03,Inflammation Plate MCE,SP20299LPS,N06,TGR-1202,TGR-1202,2,m,b135721,1532533-67-7,571.55,PI3K,Free Base,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16,6,14,"TGR-1202 is a novel <b>PI3K_</b> inhibitor; with <b>IC<sub>50</sub></b> and <b>EC<sub>50</sub></b> of 22.2 nM and 24.3 nM; respectively; Also active against <b>CK1_</b>; with an <b>EC<sub>50</sub></b> value of 6.0 _M.
HYCPK547 1:5 Dilution,Plate 3,G04,Inflammation Plate MCE,SP20299LPS,N07,Famotidine,Famotidine,2,m,b144214,76824-35-6,337.45,Histamine Receptor;Histamine Receptor,Free Base,N=C(NS(=O)(N)=O)CCSCC1=CSC(NC(N)=N)=N1,7,14,"Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
HYCPK548 1:5 Dilution,Plate 4,G04,Inflammation Plate MCE,SP20299LPS,N08,Well_N08,Well_N08,-1,m,,,,,,,8,14
HYCPK547 1:5 Dilution,Plate 3,G05,Inflammation Plate MCE,SP20299LPS,N09,WYE-125132,WYE-125132,2,m,b138269,1144068-46-1,519.6,mTOR,Free Base,O=C(NC1=CC=C(C2=NC(N3CC4CCC(C3)O4)=C5C(N(N=C5)C6CCC7(CC6)OCCO7)=N2)C=C1)NC,9,14,"WYE-125132 (WYE-132) is a highly potent; ATP-competitive; and specific <b>mTOR</b> kinase inhibitor (<b>IC<sub>50</sub></b>: 0.19±0.07 nM; >5;000-fold selective versus PI3Ks). 
HYCPK548 1:5 Dilution,Plate 4,G05,Inflammation Plate MCE,SP20299LPS,N10,Well_N10,Well_N10,-1,m,,,,,,,10,14
HYCPK547 1:5 Dilution,Plate 3,G06,Inflammation Plate MCE,SP20299LPS,N11,SC-514,SC-514,2,m,b148269,354812-17-2,224.3,IKK,Free Base,O=C(C1=C(N)C=C(C2=CSC=C2)S1)N,11,14,"SC-514 is a selective <b>IKK-2</b> inhibitor (<b>IC<sub>50</sub></b>=11.2±4.7 _M); which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
HYCPK548 1:5 Dilution,Plate 4,G06,Inflammation Plate MCE,SP20299LPS,N12,Well_N12,Well_N12,-1,m,,,,,,,12,14
HYCPK547 1:5 Dilution,Plate 3,G07,Inflammation Plate MCE,SP20299LPS,N13,Gardiquimod trifluoroacetate,Gardiquimod trifluoroacetate,2,m,b143912,1159840-61-5,541.44,Toll-like Receptor (TLR);HIV,Trifluoroacetate,OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N.FC(C(O)=O)(F)F.FC(C(O)=O)(F)F,13,14,"Gardiquimod trifluoroacetate is a specific <b>TLR7</b> agonist which can also inhibit <b>HIV-1 reverse transcriptase</b>.
HYCPK548 1:5 Dilution,Plate 4,G07,Inflammation Plate MCE,SP20299LPS,N14,Well_N14,Well_N14,-1,m,,,,,,,14,14
HYCPK547 1:5 Dilution,Plate 3,G08,Inflammation Plate MCE,SP20299LPS,N15,MRT67307,MRT67307,2,m,b140344,1190378-57-4,464.6,ULK;Autophagy;IKK,Free Base,O=C(NCCCNC1=NC(NC2=CC=CC(CN3CCOCC3)=C2)=NC=C1C4CC4)C5CCC5,15,14,"MRT67307 is a dual inhibitor of the <b>IKK_</b> and <b>TBK-1</b>; which mediates the phosphorylation of interferon regulatory factor 3 (IRF3); with <b>IC<sub>50</sub></b> values of 160 and 19 nM when assayed at 0.1 mM ATP in vitro; and also targets ULK1 and ULK2 with high potency (IC<sub>50</sub> values of 45 and 38 nM; respectively). 
HYCPK548 1:5 Dilution,Plate 4,G08,Inflammation Plate MCE,SP20299LPS,N16,Well_N16,Well_N16,-1,m,,,,,,,16,14
HYCPK547 1:5 Dilution,Plate 3,G09,Inflammation Plate MCE,SP20299LPS,N17,TAK-242,TAK-242,2,m,b143691,243984-11-4,361.82,Autophagy;Toll-like Receptor (TLR),Free Base,O=S([C@H]1C(C(OCC)=O)=CCCC1)(NC2=CC=C(C=C2Cl)F)=O,17,14,"TAK-242 is a potent <b>TLR4</b> signaling inhibitor; selectively inhibits the TLR4-mediated production of cytokines and NO.
HYCPK548 1:5 Dilution,Plate 4,G09,Inflammation Plate MCE,SP20299LPS,N18,Well_N18,Well_N18,-1,m,,,,,,,18,14
HYCPK547 1:5 Dilution,Plate 3,G10,Inflammation Plate MCE,SP20299LPS,N19,GS-9973,GS-9973,2,m,b136397,1229208-44-9,411.46,Syk,Free Base,C12=NC=CN1C=C(C3=CC4=C(C=C3)C=NN4)N=C2NC5=CC=C(N6CCOCC6)C=C5,19,14,"GS-9973 is an orally bioavailable; selective¾<b>Syk</b>¾inhibitor with¾<b>IC<sub>50</sub></b>¾of 7.7 nM.
HYCPK548 1:5 Dilution,Plate 4,G10,Inflammation Plate MCE,SP20299LPS,N20,Well_N20,Well_N20,-1,m,,,,,,,20,14
HYCPK547 1:5 Dilution,Plate 3,G11,Inflammation Plate MCE,SP20299LPS,N21,AZD-1480,AZD-1480,2,m,b145169,935666-88-9,348.77,JAK;JAK;JAK,Free Base,ClC1=C(N=C(N=C1)N[C@@H](C)C2=NC=C(C=N2)F)NC3=NNC(C)=C3,21,14,"AZD-1480 is a novel ATP-competitive <b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of < 0.4 nM; selectively against JAK3 and Tyk2; and to a smaller extent against JAK1.
HYCPK548 1:5 Dilution,Plate 4,G11,Inflammation Plate MCE,SP20299LPS,N22,Well_N22,Well_N22,-1,m,,,,,,,22,14
HYCPK547,Plate 1,H01,Inflammation Plate MCE,SP20299LPS,O01,DMSO_O01,DMSO_O01,-1,m,,,,,,,1,15
HYCPK548,Plate 2,H01,Inflammation Plate MCE,SP20299LPS,O02,DMSO_O02,DMSO_O02,-1,m,,,,,,,2,15
HYCPK547,Plate 1,H02,Inflammation Plate MCE,SP20299LPS,O03,PF06650833,PF06650833,10,m,b145688,1817626-54-2,361.37,IRAK;IRAK,Free Base,NC(C1=C(OC)C=C2C(C=CN=C2OC[C@@H]3[C@H](CC)[C@H](F)C(N3)=O)=C1)=O,3,15,"PF06650833 is an inhibitor of <b>Interleukin-1 receptor associated kinase 4 (IRAK4)</b>; and used to treat diseases such as rheumatoid arthritis; lupus; and lymphomas.
HYCPK548,Plate 2,H02,Inflammation Plate MCE,SP20299LPS,O04,Well_O04,Well_O04,-1,m,,,,,,,4,15
HYCPK547,Plate 1,H03,Inflammation Plate MCE,SP20299LPS,O05,QNZ,QNZ,10,m,b135768,545380-34-5,356.42,TNF Receptor;NF-_B,Free Base,NC1=CC2=C(NCCC3=CC=C(OC4=CC=CC=C4)C=C3)N=CN=C2C=C1,5,15,"QNZ shows strong inhibitory effects on <b>NF-_B</b> transcriptional activation and <b>TNF-_</b> production with <b>IC<sub>50</sub></b>s of 11 and 7 nM; respectively. EVP4593 is a neuroprotective inhibitor of <b>SOC</b> channel.
HYCPK548,Plate 2,H03,Inflammation Plate MCE,SP20299LPS,O06,Well_O06,Well_O06,-1,m,,,,,,,6,15
HYCPK547,Plate 1,H04,Inflammation Plate MCE,SP20299LPS,O07,Baricitinib (phosphate),Baricitinib (phosphate),10,m,b142086,1187595-84-1,469.41,JAK;JAK;JAK,Phosphate,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1.O=P(O)(O)O,7,15,"Baricitinib phosphate is a selective orally bioavailable <b>JAK1</b>/<b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of 5.9 nM and 5.7 nM; respectively.
HYCPK548,Plate 2,H04,Inflammation Plate MCE,SP20299LPS,O08,Well_O08,Well_O08,-1,m,,,,,,,8,15
HYCPK547,Plate 1,H05,Inflammation Plate MCE,SP20299LPS,O09,1400W (Dihydrochloride),1400W (Dihydrochloride),10,m,b136462,214358-33-5,250.17,NO Synthase,Hydrochloride,CC(NCC1=CC=CC(CN)=C1)=N.[H]Cl.[H]Cl,9,15,"1400W dihydrochloride is a potent and selective inhibitor of human inducible <b>NO synthase</b> with <b>K<sub>i</sub></b> values of 7 nM.
HYCPK548,Plate 2,H05,Inflammation Plate MCE,SP20299LPS,O10,Well_O10,Well_O10,-1,m,,,,,,,10,15
HYCPK547,Plate 1,H06,Inflammation Plate MCE,SP20299LPS,O11,Eucalyptol,Eucalyptol,10,m,b139085,470-82-6,154.25,Interleukin Related;5-HT Receptor;5-HT Receptor;Potassium Channel;TNF Receptor,Free Base,CC1(C)OC2(C)CCC1CC2,11,15,"Eucalyptol is an inhibitor of <b>5-HT<sub>3</sub> receptor</b> ;<b>potassium channel</b>; <b>TNF-_</b> and <b>IL-1_</b>.
HYCPK548,Plate 2,H06,Inflammation Plate MCE,SP20299LPS,O12,Well_O12,Well_O12,-1,m,,,,,,,12,15
HYCPK547,Plate 1,H07,Inflammation Plate MCE,SP20299LPS,O13,VX-745,VX-745,10,m,b133329,209410-46-8,436.26,p38 MAPK,Free Base,O=C1N=CN(C(C=C2)=C1C3=C(Cl)C=CC=C3Cl)N=C2SC4=CC=C(F)C=C4F,13,15,"VX-745 is a potent and selective inhibitor of <b>p38_</b>; and possesses anti-inflammatory activity.
HYCPK548,Plate 2,H07,Inflammation Plate MCE,SP20299LPS,O14,Well_O14,Well_O14,-1,m,,,,,,,14,15
HYCPK547,Plate 1,H08,Inflammation Plate MCE,SP20299LPS,O15,Resiquimod,Resiquimod,10,m,b134198,144875-48-9,314.38,Toll-like Receptor (TLR),Free Base,OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N,15,15,"Resiquimod is a Toll-like receptor 7 and 8 (<b>TLR7/TLR8</b>) agonist that induces the levels of cytokines such as TNF-_; IL-6 and IFN-_.
HYCPK548,Plate 2,H08,Inflammation Plate MCE,SP20299LPS,O16,Well_O16,Well_O16,-1,m,,,,,,,16,15
HYCPK547,Plate 1,H09,Inflammation Plate MCE,SP20299LPS,O17,Salidroside,Salidroside,10,m,b142312,10338-51-9,300.3,mTOR,Free Base,"#473HsXqZ8hy14XqZ8hy14XqZ8fJUWhOZ+fAW4+0Z+/QHp8QHvP51FXqZ8fJUH45
HYCPK548,Plate 2,H09,Inflammation Plate MCE,SP20299LPS,O18,Well_O18,Well_O18,-1,m,,,,,,,18,15
HYCPK547,Plate 1,H10,Inflammation Plate MCE,SP20299LPS,O19,ZM39923 (hydrochloride),ZM39923 (hydrochloride),10,m,b142270,1021868-92-7,367.91,JAK;JAK;JAK,Hydrochloride,O=C(C1=CC=C2C=CC=CC2=C1)CCN(C(C)C)CC3=CC=CC=C3.[H]Cl,19,15,"ZM39923 hydrochloride is a <b>JAK3</b> inhibitor; with a <b>pIC<sub>50</sub></b> of 7.1; also potently inhibits tissue transglutaminase (<b>TGM2</b>) with an <b>IC<sub>50</sub></b> of 10 nM.
HYCPK548,Plate 2,H10,Inflammation Plate MCE,SP20299LPS,O20,Well_O20,Well_O20,-1,m,,,,,,,20,15
HYCPK547,Plate 1,H11,Inflammation Plate MCE,SP20299LPS,O21,JNJ-7777120,JNJ-7777120,10,m,b145962,459168-41-3,277.75,Histamine Receptor;Histamine Receptor,Free Base,O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N3CCN(C)CC3,21,15,"JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM; exhibits >1000-fold selectivity over the other histamin receptors.
HYCPK548,Plate 2,H11,Inflammation Plate MCE,SP20299LPS,O22,Well_O22,Well_O22,-1,m,,,,,,,22,15
HYCPK547 1:5 Dilution,Plate 3,H01,Inflammation Plate MCE,SP20299LPS,P01,DMSO_P01,DMSO_P01,-1,m,,,,,,,1,16
HYCPK548 1:5 Dilution,Plate 4,H01,Inflammation Plate MCE,SP20299LPS,P02,DMSO_P02,DMSO_P02,-1,m,,,,,,,2,16
HYCPK547 1:5 Dilution,Plate 3,H02,Inflammation Plate MCE,SP20299LPS,P03,PF06650833,PF06650833,2,m,b145688,1817626-54-2,361.37,IRAK;IRAK,Free Base,NC(C1=C(OC)C=C2C(C=CN=C2OC[C@@H]3[C@H](CC)[C@H](F)C(N3)=O)=C1)=O,3,16,"PF06650833 is an inhibitor of <b>Interleukin-1 receptor associated kinase 4 (IRAK4)</b>; and used to treat diseases such as rheumatoid arthritis; lupus; and lymphomas.
HYCPK548 1:5 Dilution,Plate 4,H02,Inflammation Plate MCE,SP20299LPS,P04,Well_P04,Well_P04,-1,m,,,,,,,4,16
HYCPK547 1:5 Dilution,Plate 3,H03,Inflammation Plate MCE,SP20299LPS,P05,QNZ,QNZ,2,m,b135768,545380-34-5,356.42,TNF Receptor;NF-_B,Free Base,NC1=CC2=C(NCCC3=CC=C(OC4=CC=CC=C4)C=C3)N=CN=C2C=C1,5,16,"QNZ shows strong inhibitory effects on <b>NF-_B</b> transcriptional activation and <b>TNF-_</b> production with <b>IC<sub>50</sub></b>s of 11 and 7 nM; respectively. EVP4593 is a neuroprotective inhibitor of <b>SOC</b> channel.
HYCPK548 1:5 Dilution,Plate 4,H03,Inflammation Plate MCE,SP20299LPS,P06,Well_P06,Well_P06,-1,m,,,,,,,6,16
HYCPK547 1:5 Dilution,Plate 3,H04,Inflammation Plate MCE,SP20299LPS,P07,Baricitinib (phosphate),Baricitinib (phosphate),2,m,b142086,1187595-84-1,469.41,JAK;JAK;JAK,Phosphate,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1.O=P(O)(O)O,7,16,"Baricitinib phosphate is a selective orally bioavailable <b>JAK1</b>/<b>JAK2</b> inhibitor with <b>IC<sub>50</sub></b> of 5.9 nM and 5.7 nM; respectively.
HYCPK548 1:5 Dilution,Plate 4,H04,Inflammation Plate MCE,SP20299LPS,P08,Well_P08,Well_P08,-1,m,,,,,,,8,16
HYCPK547 1:5 Dilution,Plate 3,H05,Inflammation Plate MCE,SP20299LPS,P09,1400W (Dihydrochloride),1400W (Dihydrochloride),2,m,b136462,214358-33-5,250.17,NO Synthase,Hydrochloride,CC(NCC1=CC=CC(CN)=C1)=N.[H]Cl.[H]Cl,9,16,"1400W dihydrochloride is a potent and selective inhibitor of human inducible <b>NO synthase</b> with <b>K<sub>i</sub></b> values of 7 nM.
HYCPK548 1:5 Dilution,Plate 4,H05,Inflammation Plate MCE,SP20299LPS,P10,Well_P10,Well_P10,-1,m,,,,,,,10,16
HYCPK547 1:5 Dilution,Plate 3,H06,Inflammation Plate MCE,SP20299LPS,P11,Eucalyptol,Eucalyptol,2,m,b139085,470-82-6,154.25,Interleukin Related;5-HT Receptor;5-HT Receptor;Potassium Channel;TNF Receptor,Free Base,CC1(C)OC2(C)CCC1CC2,11,16,"Eucalyptol is an inhibitor of <b>5-HT<sub>3</sub> receptor</b> ;<b>potassium channel</b>; <b>TNF-_</b> and <b>IL-1_</b>.
HYCPK548 1:5 Dilution,Plate 4,H06,Inflammation Plate MCE,SP20299LPS,P12,Well_P12,Well_P12,-1,m,,,,,,,12,16
HYCPK547 1:5 Dilution,Plate 3,H07,Inflammation Plate MCE,SP20299LPS,P13,VX-745,VX-745,2,m,b133329,209410-46-8,436.26,p38 MAPK,Free Base,O=C1N=CN(C(C=C2)=C1C3=C(Cl)C=CC=C3Cl)N=C2SC4=CC=C(F)C=C4F,13,16,"VX-745 is a potent and selective inhibitor of <b>p38_</b>; and possesses anti-inflammatory activity.
HYCPK548 1:5 Dilution,Plate 4,H07,Inflammation Plate MCE,SP20299LPS,P14,Well_P14,Well_P14,-1,m,,,,,,,14,16
HYCPK547 1:5 Dilution,Plate 3,H08,Inflammation Plate MCE,SP20299LPS,P15,Resiquimod,Resiquimod,2,m,b134198,144875-48-9,314.38,Toll-like Receptor (TLR),Free Base,OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N,15,16,"Resiquimod is a Toll-like receptor 7 and 8 (<b>TLR7/TLR8</b>) agonist that induces the levels of cytokines such as TNF-_; IL-6 and IFN-_.
HYCPK548 1:5 Dilution,Plate 4,H08,Inflammation Plate MCE,SP20299LPS,P16,Well_P16,Well_P16,-1,m,,,,,,,16,16
HYCPK547 1:5 Dilution,Plate 3,H09,Inflammation Plate MCE,SP20299LPS,P17,Salidroside,Salidroside,2,m,b142312,10338-51-9,300.3,mTOR,Free Base,"#473HsXqZ8hy14XqZ8hy14XqZ8fJUWhOZ+fAW4+0Z+/QHp8QHvP51FXqZ8fJUH45
HYCPK548 1:5 Dilution,Plate 4,H09,Inflammation Plate MCE,SP20299LPS,P18,Well_P18,Well_P18,-1,m,,,,,,,18,16
HYCPK547 1:5 Dilution,Plate 3,H10,Inflammation Plate MCE,SP20299LPS,P19,ZM39923 (hydrochloride),ZM39923 (hydrochloride),2,m,b142270,1021868-92-7,367.91,JAK;JAK;JAK,Hydrochloride,O=C(C1=CC=C2C=CC=CC2=C1)CCN(C(C)C)CC3=CC=CC=C3.[H]Cl,19,16,"ZM39923 hydrochloride is a <b>JAK3</b> inhibitor; with a <b>pIC<sub>50</sub></b> of 7.1; also potently inhibits tissue transglutaminase (<b>TGM2</b>) with an <b>IC<sub>50</sub></b> of 10 nM.
HYCPK548 1:5 Dilution,Plate 4,H10,Inflammation Plate MCE,SP20299LPS,P20,Well_P20,Well_P20,-1,m,,,,,,,20,16
HYCPK547 1:5 Dilution,Plate 3,H11,Inflammation Plate MCE,SP20299LPS,P21,JNJ-7777120,JNJ-7777120,2,m,b145962,459168-41-3,277.75,Histamine Receptor;Histamine Receptor,Free Base,O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N3CCN(C)CC3,21,16,"JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM; exhibits >1000-fold selectivity over the other histamin receptors.
HYCPK548 1:5 Dilution,Plate 4,H11,Inflammation Plate MCE,SP20299LPS,P22,Well_P22,Well_P22,-1,m,,,,,,,22,16
